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ABSTRACT 
Background and aims. Healthcare-associated infections (HAIs) are known to 
increase the risk for patient morbidity and mortality in different healthcare settings 
and thereby to cause additional costs. HAIs typically affect patients with severe 
underlying conditions, such as patients treated in intensive care units, or patients 
who have undergone medical procedures, e.g., surgery. HAIs are prevalent also 
among pediatric patients, but the distribution of the types of infection and the 
causative agents differ from those detected in adults. The aim of this study was to 
obtain information on pediatric HAIs in Finland through an assessment of the 
surveillance of bloodstream infections (BSIs), through two outbreak investigations 
in a neonatal intensive care unit (NICU), and through a study of postoperative HAIs 
after open-heart surgery. 
Methods. The Hospital for Children and Adolescents of the Helsinki University 
Central Hospital has participated in the BSI surveillance of the Finnish Hospital 
Infection Program since 1999. These data were utilized in all studies. The 
epidemiological features of pediatric BSIs were assessed. For the outbreak 
investigations, case definitions were set and data collected from microbiological and 
clinical records. The antimicrobial susceptibilities of the Serratia marcescens and 
the Candida parapsilosis isolates were determined. The S. marcescens isolates were 
genotyped with pulsed-field gel electrophoresis and the C. parapsilosis blood 
culture isolates (obtained between the years 1990 and 2002) with Southern blot 
hybridization by use of a DNA fingerprinting probe. Patient charts were reviewed 
for the case-control and cohort studies during the outbreak investigations, as well as 
for those patients who acquired surgical site infections (SSIs) after having 
undergone open-heart surgery. Also a prospective postdischarge study was 
conducted to detect postoperative HAIs after open-heart surgery. 
Results. During 1999-2006, the overall annual BSI rate was 1.6/1,000 patient-days 
(range by year, 1.2–2.1). High rates (average, 4.9 and 3.2 BSIs/1,000 patient-days) 
were detected in hematology and neonatology units. Coagulase-negative 
staphylococci were the most common pathogens both hospital-wide and in each 
patient group. The overall mortality was 5%. The genotyping of the 15 S. 
marcescens isolates revealed three independent clusters. All of the 26 C. 
 parapsilosis isolates studied proved to be indistinguishable. No common source was 
identified for either of the outbreaks, but the NICU was overcrowded during the S. 
marcescens clusters. In both investigations, low birth weight and prematurity were 
identified as risk factors. A negative correlation between C. parapsilosis BSIs and 
fluconazole use in the NICU was detected, and the isolates derived from a single 
initially susceptible strain became less susceptible to fluconazole over time. Eighty 
postoperative HAIs, including all severe infections, were detected during 
hospitalization after open-heart surgery; 34% of those HAIs were SSIs and 25% 
were BSIs. The postdischarge study found 65 infections likely to be associated with 
hospitalization. The majority (89%) of them were viral respiratory or gastrointestinal 
infections, and these often led to rehospitalizations. Of the SSIs, 20% were detected 
after discharge. 
Conclusions. The annual hospital-wide BSI rates were stable, and the significant 
variation detected in some units could not be seen in overall rates. Further studies 
with data adequately adjusted for risk factors are needed to assess BSI rates in the 
patient groups with the highest rates (hematology, neonatology). The outbreak 
investigations showed that horizontal transmission was common in the NICU. 
Overcrowding and lapses in hand hygiene probably contributed to the spreading of 
the pathogens. Following long-term use of fluconazole in the NICU, resistance to 
fluconazole developed in C. parapsilosis. Almost one-fourth of the patients who 
underwent open-heart surgery acquired at least one HAI. All severe HAIs were 
detected during hospitalization. The postdischarge study found numerous viral 
infections, which often led to rehospitalization. Only superficial SSIs, which did not 
affect the patient outcome, were detected after discharge, suggesting that routine 
postdischarge surveillance may not be necessary in this patient group. 
 
Keywords: bacteremia, cross infection, epidemiologic studies, fungemia, infection 
control, molecular epidemiology, neonatal intensive care, pediatric hospitals, 
surgical site infection 
 
 
 
 
 
 
 Emmi Sarvikivi, Healthcare-associated infections in pediatrics 
Kansanterveyslaitoksen julkaisuja, A11/2008, 93 sivua 
ISBN 978-951-740-803-5; 978-951-740-804-2 (pdf-versio) 
ISSN 0359-3584; 1458-6290 (pdf-versio) 
http://www.ktl.fi/portal/4043 
TIIVISTELMÄ 
Hoitoon liittyvät infektiot eli sairaalainfektiot lisäävät potilaiden sairastavuutta ja 
kuolleisuutta terveydenhuollon eri laitoksissa. Sairaalainfektioita esiintyy erityisesti 
kirurgisia toimenpiteitä tai tehohoitoa tarvitsevilla potilailla sekä potilailla, joiden 
vastustuskyky on perussairauksien vuoksi heikentynyt. Lasten sairaalainfektioiden 
aiheuttajat ja infektiotyypit poikkeavat aikuisten infektioista. Tämän tutkimuksen 
tavoitteena oli selvittää sairaalainfektioiden esiintyvyyttä suomalaisessa 
lastensairaalassa eri potilasryhmien ja infektiotyyppien osalta. Väitöskirja koostuu 
neljästä osatyöstä: veriviljelypositiivisten infektioiden seurantatutkimuksesta, 
kahdesta vastasyntyneiden teho-osastolla tehdystä epidemiaselvityksestä sekä 
sydänleikattujen lasten leikkauksenjälkeisiä sairaalainfektioita käsittelevästä 
tutkimuksesta. 
Tutkimusaineisto kerättiin Helsingin yliopistollisen keskussairaalan Lasten ja 
nuorten sairaalassa (LNS) vuosina 1999–2006. LNS on osallistunut valtakunnallisen 
sairaalainfektio-ohjelman veriviljelypositiivisten sairaalainfektioiden seurantaan 
vuodesta 1999 lähtien, ja tätä seuranta-aineistoa käytettiin kaikissa väitöskirjan 
osatöissä. LNS:ssa 1999–2006 todettujen veriviljelypositiivisten sairaalainfektioiden 
epidemiologisia piirteitä tarkasteltiin sekä koko sairaalassa että eri yksiköissä. 
Vastasyntyneiden teho-osastolla ilmenneitä Serratia marcescens ja Candida 
parapsilosis -epidemioita tutkittiin tapaus-verrokki- ja kohorttitutkimusasetelmien 
avulla, tiedot tutkimusta varten kerättiin tapausmääritelmän perusteella valittujen 
potilaiden laboratoriovastauksista ja sairauskertomuksista. S. marcescens ja C. 
parapsilosis -kantojen mikrobilääkeherkkyydet määritettiin ja kannat tyypitettiin 
DNA-pohjaisten menetelmien avulla. Avosydänleikkauksen läpikäyneiden lasten 
sairaalainfektioita selvitettiin sekä hoitojakson ajalta että kotiutuksen jälkeen. 
Hoitojakson aikana ilmenneet leikkausalueen infektiot varmistettiin tarkastelemalla 
sairauskertomuksia, ja kotiutuksen jälkeiset infektiot kartoitettiin kotiutusvaiheessa 
jaetun kyselylomakkeen avulla. 
Kahdeksan vuoden seuranta-aikana veriviljelypositiivisten infektioiden esiintyvyys 
oli 1,6 infektiota 1000 hoitopäivää kohden (vaihteluväli vuosittain: 1,2-2,1). 
Esiintyvyys oli korkeampi hematologisia potilaita (4,9 infektiota/1000 hoitopäivää) 
ja sairaita vastasyntyneitä hoitavissa yksiköissä (3,2 infektiota/1000 hoitopäivää). 
 Koagulaasinegatiiviset staflylokokit olivat yleisimpiä taudinaiheuttajia. Veriviljely-
positiivisiin infektioihin liittyvä tapauskuolleisuus oli 5 %. Vastasyntyneiden teho-
osastolla todettiin kantojen tyypityksen perusteella kolme itsenäistä S. marcescens -
bakteerin aiheuttamaa epidemiaa. Kaikki 26 tutkittua C. parapsilosis -kantaa olivat 
geneettisesti identtisiä, mutta herkkyysmääritykset osoittivat flukonatsoliresistenssin 
kehittymisen ajan kuluessa. Veriviljelypositiivisten C. parapsilosis -infektioiden 
esiintyminen ja flukonatsoliestolääkityksen käyttö korreloivat käänteisesti. 
Yhdellekään epidemialle ei löytynyt selvää lähdettä. Osasto oli kuitenkin 
epidemioiden aikana ajoittain ylikuormitettu. Avosydänleikatuilla potilailla todettiin 
80 leikkauksen jälkeiseen hoitojaksoon liittyvää sairaalainfektiota: 34 % näistä oli 
leikkausalueen infektioita ja 25 % veriviljelypositiivisia infektioita. Kotiutuksen 
jälkeisessä kyselytutkimuksessa 65 potilaalla ilmeni kolmen vuorokauden kuluessa 
kotiutuksesta infektio-oireita, joista valtaosa (89 %) oli todennäköisesti virusten 
aiheuttamia hengitystie- tai suolistoinfektioita. Kaikki vakavat infektiot todettiin 
sairaalajakson aikana, mutta kotiutuksen jälkeen todetuista virusinfektioista 
viidesosa johti uuteen sairaalahoitojaksoon. Leikkausalueen infektioista 20 % 
todettiin kotiutuksen jälkeisessä seurannassa. 
Tutkimus osoitti, että veriviljelypositiivisten sairaalainfektioiden esiintyvyys pysyi 
LNS:ssa seurantajakson aikana vakaalla tasolla. Hematologisia potilaita ja sairaita 
vastasyntyneitä hoitavissa yksiköissä esiintyvyys oli huomattavasti keskimääräistä 
suurempi, ja näissä ryhmissä ilmeni myös suuria vuosittaisia vaihteluja 
infektioluvuissa. Näiden potilasryhmien yksityiskohtainen tarkastelu ei kuitenkaan 
ollut mahdollista, koska aineistoa ei voitu mukauttaa riskitekijöiden suhteen 
potilasjoukossa vuosittain esiintyvän vaihtelun hallitsemiseksi. Epidemiaselvitykset 
osoittivat, että potilaasta toiseen tapahtuva tartuntareitti oli tavallinen, ja että osaston 
ylikuormitus sekä siihen liittyvät ongelmat käsihygienian toteutumisessa 
todennäköisesti edesauttoivat epidemioiden leviämistä. Flukonatsolin pitkäaikainen 
käyttö osastolla johti flukonatsoliresistenttien C. parapsilosis -alatyyppien 
kehittymiseen. Avosydänleikatuista lapsista jopa joka neljäs sai sairaalainfektion 
leikkauksen jälkeen. Vakavat infektiot todettiin sairaalajakson aikana, mutta 
kotiutuksen jälkeen esiintyi runsaasti virusinfektioita, jotka aiheuttivat usein uuden 
sairaalahoitojakson. Vakavia leikkausalueen infektioita ei todettu kotiutuksen 
jälkeen, eikä rutiininomainen kotiutuksen jälkeinen seuranta siten välttämättä ole 
tarpeellista tämän toimenpideryhmän osalta. 
 
Avainsanat: infektioepidemiologia, infektioiden torjunta, lastensairaala, 
leikkausalueen infektio, risti-infektio, sairaalainfektio, tyypitysmenetelmä, 
vastasyntyneiden tehohoito, veriviljelypositiivinen infektio 
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1 INTRODUCTION 
Healthcare-associated infections (HAIs) are the most common complications 
affecting hospitalized patients [1]. In the United States, the HAI rate has been 
reported to range from 4.5 to 5.5 per 100 admissions during 1975–2002 [2, 3]. HAI 
rates vary widely between different patient populations, with the highest rates 
usually occurring in intensive care units (ICUs) [3]. This also applies to pediatric 
patients: patients treated in neonatal intensive care units (NICUs) or pediatric 
intensive care units (PICUs) are at the highest risk for HAIs [4]. Bloodstream 
infections (BSIs) are the most common HAIs in these settings [5-8], often leading to 
increased morbidity and mortality [9-11] as well as long-term consequences [12], 
and also resulting in pain and suffering of the child and the family. Furthermore, 
prolonged need of hospitalization due to HAIs may give rise to substantial additional 
costs [13-16]. 
Surgical site infections account for up to 40% of HAIs in surgical patients [17]. In 
adults undergoing coronary artery bypass surgery, SSIs reportedly occur after 8%–
10% of procedures [18, 19], and a considerable proportion of these infections was 
reportedly detected after discharge. Pediatric studies on open-heart surgery patients 
to date have reported lower SSI rates [20-23], suggesting that other types of HAI 
predominate in these patients [22-24]. However, none of these studies had 
conducted postdischarge surveillance, which may have affected the SSI rates. 
Only a small proportion of HAIs occur as epidemics, but often the consequences 
could be devastating for the affected patients [25, 26]. Systematic analysis of such 
events can help in controlling them and may lead to a re-evaluation of prevailing 
infection control practices [27].  
Surveillance of HAIs has proved essential in infection control; by determining the 
baseline HAI rates, changes in the rates can be detected and further measures 
introduced [28]. Recent reports suggest that the effect of surveillance in reducing 
HAI rates is significant, and that at least 20% of the HAIs could be preventable [29, 
30]. For some HAI types, the proportion of potentially preventable infections may 
be even larger, up to 95% [31]. National HAI surveillance systems have been 
established in the US since the 1970s and in Europe since the 1990s [32]. The 
Finnish Hospital Infection Program (SIRO) began in 1997; the national database 
includes systematically collected information on healthcare-associated BSIs and 
SSIs as reported by the participating hospitals since 1999.  
The purpose of this study was to assess the epidemiology of pediatric HAIs in the 
largest pediatric hospital in Finland, which, along with the other four tertiary care 
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centers, is responsible for the care of the most severely ill patients. Some functions, 
such as open-heart surgery and organ transplants, are nationally centered in this 
hospital serving a population of 5.3 million. SIRO surveillance data on BSIs were 
available for over eight years, thus permitting evaluation of the impact of the 
surveillance. The epidemics confronted in the NICU of the hospital were 
investigated. A prospective postdischarge study was conducted on the infections 
after open-heart surgery, and the total burden of postoperative HAIs in this patient 
population was investigated. 
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2 REVIEW OF THE LITERATURE 
2.1 HEALTHCARE-ASSOCIATED INFECTIONS IN 
CHILDREN 
2.1.1 General principles of healthcare-associated infections 
D e f i n i t i o n  o f  a  h e a l t h c a r e - a s s o c i a t e d  i n f e c t i o n  
A HAI, or nosocomial infection, is defined as a localized or systemic pathological 
reaction that results from the presence of a microorganism or its toxin and that was 
not incubating or present at the time of admission to the hospital [33, 34]. An 
infection that is acquired in the hospital but becomes evident only after discharge, is 
also considered nosocomial. The incubation period varies with the type of pathogen, 
and each infection must be assessed individually for evidence that links it to 
hospitalization or healthcare-associated intervention. Most bacterial HAIs become 
evident 48 hours or more after admission, and consequently, a time limit of 48 hours 
has been applied as a rule of thumb [35]. 
I n f e c t i o n  v s .  c o l o n i z a t i o n  
Infection implies the replication of organisms in the tissues of a host; the related 
clinical manifestation is known as a disease. Colonization is defined as the presence 
of microorganisms in or on the host without causing clinical expression or a detected 
immune response. Colonization can be differentiated from subclinical infection by 
defining an immune response, such as a serologic reaction. If such information is not 
available, it is customary to use the term colonization [33]. 
S o u r c e s  a n d  m o d e s  o f  t r a n s m i s s i o n  
HAIs can be caused by endogenous or exogenous organisms. Endogenous infections 
usually occur as a result of healthcare-associated interventions (e.g., surgical 
procedures or the insertion of vascular catheters or other indwelling devices) [34], 
by colonization and subsequent infection with microorganisms from the hospital 
environment due to immunosuppression, or by normal flora altered through 
antimicrobial therapy [36]. Exogenous infections result from the transmission of 
organisms from the hospital environment [34]. 
The transmission of exogenous organisms is also called horizontal or cross-
transmission. The source of the microorganism may be human (e.g., an infected 
patient, the index case) or environmental (e.g., contaminated devices or infusates). 
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Colonized patients or healthcare workers (HCWs) may serve as reservoirs or 
secondary sources [37]. Transmission may occur through direct contact, a common 
source, air or vectors, or sometimes through a combination of these routes [38, 39] 
(Figure 1). Person-to-person transmission is the most common means of 
transmission and may occur either through direct physical contact with an infected 
or colonized person or through indirect contact, such as the transfer from one patient 
to another on the hands of HCWs [40]. 
 
Figure 1. 
Some possible transmission routes of Staphylococcus epidermidis [39], a common 
pathogen causing healthcare-associated infections. a = direct contact transmission, b = 
indirect contact transmission, c = direct airborne transmission, d = indirect airborne 
transmission. (Reproduced with permission of Dr. Göran Hedin.) 
 
 
 
 
 
 
 
 
 
C a u s a t i v e  a g e n t s  
The causative microorganisms vary depending on the type of HAI. Among the most 
common nosocomial pathogens are Eschericia coli, typical of urinary tract 
infections (UTIs), as well as Staphylococcus aureus and coagulase-negative 
staphylococci (CoNS), which are commonly isolated from many body sites [41]. 
The first national prevalence survey in Finland, conducted in 2005, identified E. 
coli, S. aureus and Enterococcus faecalis as the three most common pathogens 
causing HAIs in adult patients [42]. In pediatric studies, CoNS (20%–26%), 
Pseudomonas aeruginosa (5%–20%), S. aureus (11-15%), and Candida species 
(4%–9%) were predominant pathogens, in addition to viruses (mostly rotavirus and 
respiratory syncytial virus), which were identified in 22%–23% of all HAIs [43, 44].  
 20 
2.1.2 Importance to public health 
M o r b i d i t y  
National prevalence studies in different European countries have revealed hospital-
wide HAI rates ranging from 3.5% to 9.3% [45]. The Finnish prevalence study 
found that 8.5% of patients had at least one HAI on the day of the survey [42]. In the 
United States, the estimated number of HAIs was 1.7 million in 2002, representing a 
rate of 9.3 HAIs per 1,000 patient-days or 4.5 per 100 admissions [3]. Pediatric 
HAIs are known to differ in many ways from those detected in adult patients. In 
general, the HAI rates reported in pediatric patients have usually been lower than 
those in adults [38]. When viral infections are included, however, HAI rates in 
children are substantially higher than those in adults (up to 7 vs. 4 infections per 100 
patients) [43]. Children tend to have fewer SSIs, UTIs, and ventilator-associated 
pneumonias (VAPs) than do adults, but more BSIs, viral gastrointestinal and 
respiratory infections, and cutaneous infections [46]. Viral HAIs tend to occur in 
epidemics, and their occurrence is greatly dependent on the seasonal variation of 
community-acquired diseases [47, 48]. Strict infection control measures, including 
the early identification and isolation of potential carriers, are required to prevent the 
spread of viral pathogens [49]. 
A large Canadian study reported an overall HAI rate of 6.0 infections per 100 
admissions [43]. The HAI rate varied depending on the ward or pediatric specialty; 
more than half of the infections were detected in just 6 of the 21 wards; the highest 
HAI rate was detected in the NICU. When the HAI rate was sorted by the age of the 
patients, the HAI rate in patients under two years of age (11.5 infections per 100 
admissions) was substantially higher than in the other age groups (3.6 infections per 
100 admissions in patients aged 2 to 4 years; 2.6 infections per 100 admissions in 
patients 5 years of age or older). A European study of 17 pediatric centers reported 
an overall HAI rate of 2.5% including five types of HAI: BSIs, lower respiratory 
tract infections, UTIs, SSIs, and gastrointestinal infections [44]. 
M o r t a l i t y  
HAIs have been estimated to cause attributable mortality of 7%–9% in adults [50, 
51]. In the US, 6% of patients with at least one HAI in 2002 were reported to have 
had a cause of death associated with that HAI [3]. Few reports exist that describe 
mortality associated with HAIs in pediatric patients. A Brazilian study attributed a 
case-fatality of 2% with HAIs in general [52]. The majority of the severe HAIs (e.g., 
BSIs) associated with increased mortality occur, however, in patients with severe 
underlying conditions. Reported mortality rates associated with BSIs have been 
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substantially higher: 9%–14% in pediatric patients in general [53, 54], 18%–20% in 
PICUs [55, 56], and 8%–18% in NICUs [10, 57]. 
C o s t  
Prolongation of the hospital stay or intensive care, as well as an increased need for 
diagnostic examinations (e.g., radiology, laboratory) and antimicrobial medication, 
are the main sources of the significant additional costs associated with HAIs. HAIs 
have been estimated to prolong an average hospital stay by 3 to 23 days [50, 51, 58, 
59]. The average additional cost associated with a HAI was as high as USD 5,300 
[51]. A study conducted in a PICU found the direct cost of PICU admission 
attributable to nosocomial primary BSI to be USD 39,219 [15]. A Belgian study 
conducted in an NICU over a 24-month period found HAIs to lengthen the average 
hospital stay with an average of 24 days, and the mean additional cost of a HAI to be 
EUR 11,750 [13]. These cost-effectiveness studies have been criticized for using 
low quality data for some parameters and a lack of transparency, as well as for using 
short time-horizons and narrow economic perspectives [60]. Thus, the figures 
presented above probably overestimate the costs, but prevention of these infections 
is nevertheless likely to save not only lives, but also a significant amount of money. 
2.1.3 Patients at risk 
Children with immunological defects are at greater risk for acquiring HAIs. 
Neonates are a typical patient group at risk; several components of the immune 
system exhibit diminished functional capacity enhancing thus susceptibility to 
infections and may also affect the duration of microorganism shedding [61]. The 
basis of increased susceptibility is not fully understood, but at least the lack of pre-
existing immunological memory (adaptive immunity) as well as impaired innate 
immune mechanisms (e.g., decreased responses to pathogen-derived stimuli or 
decreased ability for sustained induction of inflammatory cytokine production) have 
been proposed to play a role [62, 63]. Due to the naïve adaptive immune system, a 
newborn infant depends on passively acquired maternal antibodies, and because the 
transmission of these antibodies to the fetus begins at approximately week 24-26 of 
gestation (reaching the adult levels only near full term) prematurely born neonates 
typically possess lower antibody levels than full term infants [64]. On the other 
hand, these passively acquired antibodies may provide inadequate protection against 
the hospital endemic microorganisms to which the infant will be exposed in the 
NICU. While healthy newborns are likely to acquire from the mother the majority of 
the microbial flora colonizing the mucosal surfaces and the skin, neonates 
hospitalized in an NICU setting are likely to acquire their endogenous microbial 
flora from endemic microorganisms present in the NICU and modified by frequent 
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exposure to antimicrobial agents [65, 66]. Moreover, NICU patients are critically ill, 
and therefore often require the use of invasive procedures, such as mechanical 
ventilation or parenteral nutrition and prolonged hospitalization, all of which are 
likely to increase the risk for acquiring a nosocomial pathogen [13, 40]. 
Patients with immunosuppressive treatments are also at an increased risk for 
contracting HAIs [38, 43]. In the Finnish patient population, children with 
hematological or other malignancies and organ transplant recipients are the most 
important subgroups receiving these treatments [67]. A major problem is treatment-
induced neutropenia, which exposes patients to life-threatening infections. As the 
intensity of modern cancer chemotherapy has increased, fungal infections have also 
become more frequent [68]. BSIs, the most prevalent HAIs in pediatric 
hematology/oncology patients, seem to be associated with the use of a central 
venous catheter (CVC) in most cases [69, 70]. 
Children with congenital anomalies could have immunological deficiencies due to 
specific syndromes (e.g., Wiscott-Aldrich, DiGeorge) or loss of protective barriers 
(e.g., cleft palate, meningomyelocele) [46]. Such children often require multiple 
hospitalizations, their hospital stays are likely to be extended, and they usually need 
surgical procedures and indwelling devices, all of which further increase the risk for 
HAIs. 
2.1.4 Bloodstream infections 
BSIs are the most common severe HAIs in children [71-73]. Advances in neonatal 
intensive care have led to the improved survival of prematurely born infants, but 
HAIs, especially BSIs, frequently complicate the hospitalization of these infants [5, 
10, 11, 64, 74-76]. Neonatal BSIs are categorized as early-onset infections, 
occurring shortly after birth as a result of perinatal infection, and as late-onset 
infections, usually occurring after the first week of life. Most early-onset infections 
become evident within the first 48–72 hours of life. Consequently, a time limit of 
three days is often used in definitions. Early and late-onset BSIs differ in risk factors 
and the distribution of causing pathogens; early-onset infections typically result 
from maternal microorganisms, most commonly Streptococcus agalactiae and E. 
coli, and are associated with obstetric complications such as chorionamnionitis, 
maternal fever, or prolonged rupture of membranes [40, 77, 78]. Late-onset BSIs are 
more likely to be acquired from the hospital environment. Coagulase-negative 
staphylococci (CoNS), Candida species, and Gram-negative bacteria (e.g., E. coli, 
Klebsiella, Pseudomonas, Enterobacter, and Serratia species) are typical pathogens; 
prematurity, low birth weight, central venous catheters, mechanical ventilation, 
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parenteral nutrition and a long hospital stay have been reported as risk factors for 
late-onset BSIs [10, 11, 79-81]. 
Late-onset BSIs are an important problem in very low birth weight (VLBW, ≤1500 
g) neonates. In a large VLBW infant population in the US, 21% of the patients had 
≥1 episodes of blood culture-positive late-onset BSI, and as many as 46% of the 
infants with the lowest gestational ages (<25 weeks) acquired at least one BSI 
episode [10]. Furthermore, infants with birth weights ≤750 g were more likely to 
have multiple episodes of BSIs. Prolongation of need for intravenous access (central 
lines) and parenteral hyperalimentation as well as mechanical ventilation were 
strongly associated with increased risk for BSI in this study. Also dexamethasone 
treatment has been reported to increase the risk for BSIs [82]. 
In particular, the smallest VLBW infants seem to be at risk for candidal BSIs [83], 
which have also been associated with both dexamethasone therapy and prolonged 
treatment with antimicrobial agents [84, 85]. The attack rate of invasive Candida 
infections over the past two decades has ranged from 3% to 17% among VLBW 
infants, and from 6% to 20% among extremely low birth weight infants (≤1,000 g), 
with a case-fatality of around 30% [10, 86-95]. The main causative agents causing 
candidemias in the VLBW infant population have been Candida albicans and 
Candida parapsilosis, and a shift towards the latter has occurred gradually [86, 96, 
97]. The characterization of C. parapsilosis outbreak strains has revealed variation 
between C. parapsilosis strains in phenotypic markers, such as biofilm production; 
such factors may also play a role in the strain’s ability to cause infection [98]. 
Candida species may colonize up to 60% of VLBW infants during the first weeks of 
their NICU stay [99]. Colonization at multiple sites and CVC colonization have 
been reported as independent risk factors for candidal BSI [100]. The use of 
fluconazole prophylaxis seems to be effective against fungal colonization as well as 
to prevent candidal BSI [91-95, 101-103]. None of the prophylaxis studies has 
reported changes in the fluconazole susceptibility of the Candida strains. However, 
fluconazole prophylaxis has been associated with increased risk for colonization 
with fungal isolates that are intrinsically resistant to fluconazole [104]. 
2.1.5 Surgical site infections 
Surgical site infections are among the most common HAIs in adult patients [17, 42, 
105]. The proportion of SSIs of all HAIs in prevalence studies across Europe has 
varied between 14% and 48%, whereas overall HAI rates were 4%–10% [45]. 
Pediatric prevalence studies have reported HAI rates of 7%–12%, of which SSIs 
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constituted 1%–17% [72, 73, 106, 107]. The overall SSI rates among children were 
approximately ten times lower than among adults in NNIS hospitals [108].  
Cardiac surgery due to congenital heart disease refers to a heterogeneous group of 
procedures, most of which are unique to pediatric patients. Many of these operations 
must be performed within the first days of life, because of the severity of the 
condition, and many of these patients require multiple operations [109]. Pediatric 
studies have reported SSI rates between 2% and 8% after cardiac surgery (Table 1). 
The risk factors for SSI in these studies included young (neonatal) age, cyanotic 
heart disease, a high ASA score, an extended preoperative hospital stay, prolonged 
duration of surgery, an open chest postoperatively, and extended mechanical 
ventilation [20-24]. However, the widely used NNIS risk index score, which 
stratifies patients according to three risk factors (an ASA score ≥3, a wound 
contamination classification of either contaminated or dirty, and a duration of 
operation longer than the 75th percentile of the duration for each operative 
procedure) [110, 111] did not seem to adequately stratify pediatric cardiac surgery 
patients [112, 113]. Similar results have been reported previously in adult patients 
with cardiothoracic operations [114]. 
 
Table 1.  
Summary of studies reporting rates of healthcare-associated infections (HAIs) after 
pediatric open-heart surgery. SSI = surgical site infection, BSI = bloodstream infection. 
No. of patients 
(procedures) 
% of patients 
with SSIs 
% of patients with 
BSIs (primary BSIs) 
% of patients 
(procedures)  
with HAIs 
Reference 
        
242  (256) 5.0 a) 7.8  (5.0) 20.2 a)  (19.1) [22] 
104 b) 4.8 15.4 c) 48.1 [23] 
335 b) 7.8 9.9 16.4 [24] 
1117 (1117) 3.4 d) d) [21] 
826  (826) 2.3 d) d) [20] 
1580 (1580) 3.0 d) d) [115] 
a)    Sternal wound infections only. Bacterial infections only. 
b)    The number of procedures not mentioned.  
c)     6 episodes of clinical sepsis included. 
d)    Only SSIs reported. 
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2.2 OUTBREAKS 
2.2.1 Definition and importance 
Epidemic HAIs, or outbreaks, are defined as hospital-acquired infections that 
represent an increase in incidence over expected rates. Nosocomial outbreaks occur 
relatively infrequently; they have been estimated to account for approximately 5% 
of all HAIs [116]. Yet, in settings such as ICUs, epidemics may account for a 
substantially higher percentage of HAIs [117]. Often these infections occur in small 
clusters, and even one episode of an uncommon infection may indicate an outbreak. 
On the other hand, if pathogens or anatomic sites of infections are not uncommon, a 
deviation from the baseline infection rate in a specific hospital unit can refer to 
epidemic transmission [116]. 
The rationale for investigating a recognized outbreak is to identify and eliminate the 
source of infection; the implementation of appropriate control measures to prevent 
further illness and death is essential. The outbreak may have ceased by the time of 
the investigation, but the decision to investigate the outbreak may still be justifiable. 
Strategies for preventing similar future outbreaks can be achieved and more about 
the diseases can be learned through outbreak investigations. Sometimes new 
diseases occur as outbreaks, and the investigation offers the opportunity to describe 
them. Other goals of the investigation may include evaluating existing prevention 
strategies or addressing public concerns about the outbreak [118]. 
An overview of published outbreak reports is required when the organism causing a 
suspected hospital outbreak has been identified. Gastmeier et al. have developed a 
systematic register of nosocomial outbreaks to assist with quick overviews [119]. 
The database covers approximately three fourths of all published outbreaks [120] 
and is regularly updated and freely accessible (http://www.outbreak-database.com). 
The database also provides structured information on the outbreaks, offering 
opportunities to search for various combinations of parameters, such as type of 
microorganism, setting, mode of transmission, type of infection, and risk factors. 
2.2.2 Outbreaks in neonatal intensive care units 
At the time of the search on 3 December 2007, the outbreak database contained 
information on 2,112 outbreaks, of which 460 were from neonatal departments. 
Thirty of these were S. marcescens outbreaks. Table 2 shows a summary of those 
outbreaks that were reported between the years 1990 and 2006 and that had occurred 
in NICUs. Most of the studies had utilized molecular typing methods to study the 
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genetic relatedness of the isolates. However, few studies identified an environmental 
source for the outbreak, even if environmental samples had been examined in all but 
one of them. 
Outbreaks of C. parapsilosis were less common; this pathogen was involved in only 
22 of the 2,112 outbreaks in the database, eight of which had occurred in an NICU 
setting (Table 3).  
Overcrowding, understaffing, and a discrepancy between workload and resources 
have been reported to be associated with unfavorable patient outcomes: increased 
numbers of HAIs [151, 152] and mortality [153, 154]. Understaffing has also been 
linked to several hospital outbreaks, including those caused by resistant 
microorganisms [155-158]. Measuring workload is difficult; at least the severity of 
illness of the patients (case-mix), the educational level of the staff (HCW skill-mix) 
and organizational factors (e.g., working shift schedule, mental stress) are likely to 
affect the workload [159]. In single NICU studies, various crude approaches have 
been used, such as calculating nurse-to-patient ratios [155] or nurse-hours per 
patient per day [151], and calculating the proportion of extra staff [156]. 
Additionally, the number of potentially hazardous contact routes, not the nurse-to-
patient ratio alone, could be a deciding factor in overcrowding situations; cohorting 
the nurses so that each nurse cares for a certain cohort of patients helps to minimize 
staff-patient contact [160]. 
2.2.3 Hand hygiene and cross-transmission 
Several studies have demonstrated the exogenous route of infection in ICUs by 
using the molecular genotyping of pathogens (Table 4). The proportion of identical 
isolates in these studies was between 9% and 72%, showing the prominent role of 
cross-transmission and suggesting that improvement in infection control procedures 
could significantly reduce the number of HAIs. The role of hand hygiene is crucial 
and has been recognized as the single most important preventive measure [161]. 
Nevertheless, compliance with hand hygiene procedures is often poor, at only 30%–
40% [162-165]. Compliance seems to vary depending on several issues: women tend 
to comply more often than men, and nurses more often than physicians or nursing 
assistants [162, 166]. In addition, working in an ICU or wearing gloves has been 
observed to be a risk factor for lack of compliance with hand hygiene [162]. Even if 
wearing gloves has been associated with a reduction in HAI rates, inappropriate use, 
such as failure to remove the gloves after patient contact or between dirty and clean 
body site care or ignoring hand hygiene after glove removal, is likely to enhance the 
transmission of pathogens [167, 168]. Alcohol-based hand rubs have been 
demonstrated to cause less skin irritation than the traditional washing  
29
  
Ta
bl
e 
4.
  
S
um
m
ar
y 
of
 c
ro
ss
-in
fe
ct
io
n 
st
ud
ie
s.
  
IC
U
 =
 in
te
ns
iv
e 
ca
re
 u
ni
t, 
N
IC
U
 =
 n
eo
na
ta
l i
nt
en
si
ve
 c
ar
e 
un
it,
 P
T 
= 
pa
tie
nt
(s
), 
H
C
W
 =
 h
ea
lth
ca
re
 w
or
ke
r(
s)
. 
St
ud
y 
pe
rio
d 
Se
tti
ng
 
So
ur
ce
 
M
ic
ro
be
s 
 
Ty
pi
ng
 
m
et
ho
d 
N
o.
 o
f 
is
ol
at
es
 
N
o.
 (%
) o
f i
so
la
te
s 
as
so
ci
at
ed
 w
ith
 
cr
os
s-
tr
an
sm
is
si
on
  
R
ef
er
en
ce
 
 
 
 
 
 
 
 
 
 
12
 m
on
th
s 
2 
ad
ul
t I
C
U
s 
In
fe
ct
ed
 a
nd
 
co
lo
ni
ze
d 
P
T 
m
ul
ti-
re
si
st
an
t G
N
B
 
R
A
P
D
-A
LF
A
 
P
FG
E
 
13
2 
32
  
(2
4)
 
[1
69
] 
12
 m
on
th
s 
1 
ad
ul
t I
C
U
 
In
fe
ct
ed
 a
nd
 
co
lo
ni
ze
d 
P
T 
G
N
B
 
R
A
P
D
-A
LF
A
 
21
5 
72
  
(3
4)
 
[1
70
] 
9 
m
on
th
s 
1 
ad
ul
t I
C
U
 
In
fe
ct
ed
 P
T 
S
. a
ur
eu
s,
 
en
te
ro
co
cc
i, 
G
N
B
 
P
FG
E
 
A
P
-P
C
R
 
10
4 
36
  
(3
5)
 
[1
71
] 
23
 m
on
th
s 
2 
N
IC
U
s 
In
fe
ct
ed
 P
T,
 
H
C
W
 (h
an
ds
)
G
N
B
 
P
FG
E
 
11
9 
(P
T)
 
26
 (H
C
W
) 
50
 (P
T)
 
5 
(H
C
W
) 
(4
2)
 
(1
9)
 
[1
72
] 
18
 m
on
th
s 
5 
ad
ul
t I
C
U
s 
In
fe
ct
ed
 a
nd
 
co
lo
ni
ze
d 
P
T 
10
 in
di
ca
to
r 
or
ga
ni
sm
s 
 
(e
.g
., 
S
. a
ur
eu
s,
 
en
te
ro
co
cc
i, 
G
N
B
) 
P
FG
E
 
A
P
-P
C
R
-A
FL
P
 
27
33
 
13
2 
 
(9
) 
[1
73
] 
12
 m
on
th
s 
1 
N
IC
U
 
In
fe
ct
ed
 a
nd
 
co
lo
ni
ze
d 
P
T 
m
ul
ti-
re
si
st
an
t G
N
B
 
P
FG
E
 
11
6 
84
  
(7
2)
 
[1
74
] 
G
N
B
 
G
ra
m
-n
eg
at
iv
e 
ba
ct
er
ia
 
R
A
P
D
- A
LF
A
 
R
an
do
m
 a
m
pl
ifi
ed
 p
ol
ym
or
ph
ic
 D
N
A
, a
ut
om
at
ed
 la
se
r f
lu
or
es
ce
nc
e 
an
al
ys
is
 
P
FG
E
 
P
ul
se
d-
fie
ld
 g
el
 e
le
ct
ro
ph
or
es
is
 
A
P
-P
C
R
 
A
rb
itr
ar
ily
 p
rim
ed
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n 
A
FL
P
 
A
m
pl
ifi
ed
 fr
ag
m
en
t-l
en
gt
h 
po
ly
m
or
ph
is
m
 
30
 31 
with soap and water [175, 176]. Use of hand rubs has been reported to result in 
higher compliance with hand hygiene [177, 178], in greater reduction in hand 
contamination compared with antimicrobial soaps [179, 180], and in reduction in 
nosocomial transmission of resistant bacteria [181]. Therefore, alcohol-based hand 
rubs are considered as the method of choice for decontaminating hands in clinical 
situations nowadays; handwashing with soap and water is, however, recommended 
whenever the hands are visibly dirty [161]. 
The most common causes of lack of compliance with hand hygiene that were 
mentioned in interviews with HCWs included poor access to hand hygiene supplies, 
skin irritation caused by hand hygiene agents, interference with the patient-nurse 
relationship, the wearing of gloves, lack of knowledge, and forgetfulness [162]. A 
survey conducted to assess the knowledge, beliefs and practices of HCWs in a large 
NICU in the US showed a discrepancy between knowledge and practice: 96% of 
HCWs believed that sterile techniques, 91% believed that gloves, and 99% thought 
that hand hygiene prevents HAIs in CVC care, but only 67% used sterile barriers in 
CVC insertions, 81% reported routine hand hygiene, and 76% reported wearing 
gloves. Moreover, the role of rings and artificial or long fingernails in increasing the 
risk for HAIs was not well known: 61% wore at least one ring, 44% wore long 
fingernails, and 8% wore artificial fingernails at work [182]. The NICU staff may 
also oppose eliminating use of jewelry and artificial nails, because changes in these 
practices extend beyond the workplace. Evidence linking HAIs with wearing 
artificial fingernails or hand jewelry can be helpful in achieving compliance [183]. 
Hand hygiene compliance rates can be improved by educational campaigns [163, 
184, 185]. The Hawthorne effect, first described in electric factory workers as early 
as in the 1930s [186], refers to the tendency of people under observation in a study 
context to behave differently from the way they otherwise do and may explain why 
the effect of educational campaigns could likely be short-lived [184]. Regular 
interaction between infection control and nursing staff on wards is important and 
may promote stricter adherence to hand hygiene than occasional campaigns [163, 
183, 187, 188].  
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2.3 SURVEILLANCE OF PEDIATRIC HEALTHCARE-
ASSOCIATED INFECTIONS 
2.3.1 Purpose and objectives of surveillance 
Surveillance, “the ongoing, systematic collection, analysis, and interpretation of 
health data essential to the planning, implementation, and evaluation of public health 
practice, closely integrated with timely dissemination of these data to those who 
need to know” [189], is a cornerstone of infection control. Surveillance enables the 
establishment of baseline HAI rates and the detection of outbreaks, assists in 
selecting treatment and prevention strategies, offers the possibility to assess the 
impact of control measures, renders comparisons between units or hospitals 
possible, and provides tools for convincing administrators of the need for additional 
resources [28, 190]. 
The Study on the Efficacy of Nosocomial Infection Control (SENIC), conducted in 
the 1970s, reported effective surveillance programs to include the following 
essential components: organized surveillance and control activities, qualified 
personnel (trained infection control physicians and nurses) to conduct the 
surveillance, and a system for reporting infection rates to clinicians; implementing 
such a program with these components reduced the hospitals’ infection rates by 32% 
[191]. The component of organized surveillance includes numerous aspects: 
assessing the population and selecting the outcome or process for surveillance to 
identify the most appropriate methods, using surveillance definitions consistently, 
and systematically collecting and managing as well as regularly analyzing the data 
in order to promptly identify possible problems [192, 193]. Furthermore, risk 
stratification (i.e., subdividing the population into groups with similar 
characteristics) is recommended [193]. Without stratification, the heterogeneity of 
the study population could render comparisons between units, or over time in a 
single unit, invalid or misleading. For example, stratification by birth weight 
categories is recommended for NICU patients, because low birth weight has proved 
to be a significant risk factor for HAIs [10, 11, 64, 74, 76, 79, 80, 194]. 
National surveillance systems for HAIs have been developed during the past decades 
in many developed countries. The first of them, the NNIS, began in the US in 1970, 
when selected acute care hospitals began reporting their HAI surveillance data to the 
national database established and maintained by the Centers for Disease Control and 
Prevention (CDC). The participation of hospitals was voluntary and confidential [195]. 
In the beginning, the NNIS surveillance was hospital-wide, meaning all patients were 
monitored for HAIs, infections at all sites were included, and overall HAI rates were 
calculated [196]. In 1986, three additional standardized protocols were introduced to 
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address the limitations of laborious hospital-wide surveillance (see also 2.3.4): the 
intensive care unit, the high-risk nursery, and the surgical patient components were 
initiated. In 2005, the NNIS was merged with two other healthcare surveillance 
systems at the CDC, the Dialysis Surveillance Network and the National Surveillance 
of Healthcare Workers, to establish the National Healthcare Safety Network (NHSN), 
which has both a Patient Safety and a Healthcare Personnel Safety surveillance 
component [197]. Within the Patient Safety component, the data are grouped into three 
module protocols: the Device-associated module, the Procedure-associated module, 
and the Medication-associated module. 
During the 1990s, national or regional networks for HAI surveillance, most of which 
were based on the NNIS model, were established in many European countries as 
well as in Canada and Australia [198]. The Hospitals in Europe Link for Infection 
Control through Surveillance (HELICS) [199] was founded in 1994 to facilitate a 
standardized approach to HAI surveillance and to encourage the development of 
new surveillance programs for HAIs [200]. Two common surveillance protocols 
have been agreed upon within HELICS: surveillance of ICU-acquired infections and 
surveillance of SSIs [199-201]. 
2.3.2 Surveillance definitions 
Standard surveillance definitions and protocols are essential for surveillance systems 
[202]. The definitions do not define clinical illness, but are used for credible and 
consistent case finding and ascertainment across institutions [203]. The surveillance 
definitions should be exact, easy to use, and unambiguous, and should allow 
different observers to obtain the same results [192]. To compare the results with 
those of other surveillance systems, the definitions should be similar to those used 
by the other systems. Most national surveillance systems have adopted the CDC 
definitions, often with local modifications. These modifications, however small, 
may affect SSI rates considerably [204, 205]. The CDC definitions of laboratory-
confirmed BSIs and clinical sepsis (Table 5) include specific criteria for patients 
under one year of age. However, the definitions may not always be appropriate for 
identifying HAIs in neonates due to certain special physiological features [6, 206]. 
Moreover, a time limit of three days is often used when defining neonatal 
nosocomial BSIs; early-onset infections are excluded because they are likely to be 
acquired vertically (from the mother), rather than horizontally (from the hospital 
environment) [10, 206]. The CDC definitions of SSI appear in Table 6. 
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Table 5.  
The Centers for Disease Control and Prevention definitions of laboratory-confirmed 
bloodstream infections and clinical sepsis [195]. 
Laboratory-confirmed bloodstream infection 
Laboratory-confirmed bloodstream infection must meet at least one of the following criteria: 
 
Criterion 1:  Patient has a recognized pathogen cultured from one or more blood cultures 
and 
organism cultured from blood is not related to an infection at another site. 
 
Criterion 2: Patient has at least one of the following signs or symptoms: fever (>38○C), chills, 
or hypotension 
and 
at least one of the following: 
a. Common skin contaminant (e.g., diphtheroids,Bacillus sp., Propionibacterium 
sp., coagulase-negative staphylococci, or micrococci) is cultured from two or 
more blood cultures drawn on separate occasions 
b. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) is 
cultured from at least one blood culture from a patient with an intravascular 
line, and the physician institutes appropriate antimicrobial therapy 
c. Positive antigen test on blood (e.g., Haemophilus influenzae, Streptococcus 
pneumoniae, Neisseria meningitidis, or group B Streptococcus) 
and 
signs and symptoms and positive laboratory results are not related to an 
infection at another site. 
 
Criterion 3:  Patient ≤1 year of age has at least one of the following signs or symptoms: fever 
(>38○C), hypothermia (<37○C), apnea, or bradycardia 
and 
at least one of the following: 
a. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) is 
cultured from two or more blood cultures drawn on separate occasions 
b. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) is 
cultured from at least one blood culture from a patient with an intravascular 
line, and physician institutes appropriate antimicrobial therapy 
c. Positive antigen test on blood (e.g., H. influenzae, S. pneumoniae, N. 
meningitidis, or group B Streptococcus) 
and 
signs and symptoms and positive laboratory results are not related to an 
infection at another site. 
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Table 5 (continued). 
Clinical sepsis 
Clinical sepsis must meet at least one of the following criteria: 
 
Criterion 1:  Patient has at least one of the following clinical signs or symptoms with no other 
recognized cause: fever (>38○C), hypotension (systolic pressure ≤90 mm Hg), or 
oliguria (<20 cm3/hr) 
and 
blood culture not done or no organisms or antigen detected in blood 
and 
no apparent infection at another site 
and 
physician institutes treatment for sepsis. 
Criterion 2:  Patient ≤1 year of age has at least one of the following clinical signs or symptoms 
with no other recognized cause: fever (>38○C), hypothermia (<37○C), apnea, or 
bradycardia 
and 
blood culture not done or no organisms or antigen detected in blood 
and 
no apparent infection at another site 
and 
physician institutes treatment for sepsis. 
 
 
2.3.3 Case finding and ascertainment 
Identification of HAIs requires the use of multiple information sources, as the 
definitions include both clinical and laboratory information. The time required for 
data collection depends on the case finding method, and the sensitivities of the 
different methods vary [192, 207]. Thus, to ensure the comparability of HAI rates 
within a surveillance system, the methods for case finding and ascertainment should 
be defined [208]. For instance, the sensitivity of a systematic chart review of all 
patients – a very time-consuming method – has been reported to be as high as 94% 
[209-211], but to drop to 71% if the chart review is selected based on the ward 
liaison and a review of laboratory reports [212]. The sensitivity of a single method 
may also vary depending on infection type or patient subpopulation. When 
prevalence study data on 15,000 patients from 72 hospitals were investigated using 
either microbiology reports or antibiotic administration as indicators, >95% of the 
patients with pneumonia, urinary tract infection or BSI were identified, and >95% of 
the HAIs of ICU patients were found. However, for SSIs the sensitivity of these 
indicators was <90%, and the overall sensitivity was as low as <80% in some 
hospitals [213]. 
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Table 6.  
The Centers for Disease Control and Prevention definitions of surgical site infections [214]. 
Superficial incisional SSI 
A superficial SSI must meet the following criteria: 
Infection occurs within 30 days after the operative procedure 
and 
involves only skin and subcutaneous tissue of the incision 
and 
patient has at least one of the following: 
a. Purulent drainage from the superficial incision 
b. Organisms isolated from an aseptically obtained culture of fluid or tissue from 
the superficial incision 
c. At least one of the following signs or symptoms of infection: pain or 
tenderness, localized swelling, redness, or heat, and superficial incision is 
deliberately opened by surgeon, unless incision is culture-negative 
d. Diagnosis of superficial incisional SSI by the surgeon or attending physician  
Deep incisional SSI 
A deep incisional SSI must meet the following criteria: 
Infection occurs within 30 days after the operative procedure if no implant* is left in 
place or within 1 year if implant is in place and the infection appears to be related 
to the operative procedure 
and 
involves deep soft tissues (e.g., fascial and muscle layers) of the incision 
and 
patient has at least one of the following: 
a. Purulent drainage from the deep incision but not from the organ/space 
component of the surgical site 
b. A deep incision spontaneously dehisces or is deliberately opened by a 
surgeon when the patient has at least one of the following signs or 
symptoms: fever (>38○C) or localized pain or tenderness, unless incision is 
culture-negative 
c. An abscess or other evidence of infection involving the deep incision is found 
on direct examination, during reoperation, or by histopathologic or radiologic 
examination 
d. Diagnosis of a deep incisional SSI by a surgeon or attending physician 
Organ/space SSI 
An organ/space SSI must meet the following criteria: 
Infection occurs within 30 days after the operative procedure if no implant* is left in 
place or within 1 year if implant is in place and the infection appears to be related 
to the operative procedure 
and 
infection involves any part of the body, excluding the skin incision, fascia, or 
muscle layers, that is opened or manipulated during the operative procedure 
and 
patient has at least one of the following: 
a. Purulent drainage from a drain that is placed through a stab wound into the 
organ/space  
b. Organisms isolated from an aseptically obtained culture of fluid or tissue in 
the organ/ space  
c. An abscess or other evidence of infection involving the organ/space that is 
found on direct examination, during reoperation, or by histopathologic or 
radiologic examination  
d. Diagnosis of an organ/space SSI by a surgeon or attending physician  
*  A nonhuman-derived implantable foreign body (e.g., prosthetic heart valve, nonhuman vascular 
graft, mechanical heart, or hip prosthesis) that is permanently placed in a patient during surgery. 
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In practice, case finding is usually performed by infection control nurses (ICNs), 
who regularly review the data sources available (microbiology reports, patient 
records, ward notifications) [28, 195]. By comparing the findings of each infection 
to the HAI definitions, they conclude whether the criteria have been fulfilled (i.e., 
whether a HAI has occurred). To obtain high quality data, ICNs require regular 
training, counseling, and updating of their skills [203, 215]. Case finding, however, 
depends exclusively on the data present in the hospital information system, and 
differences in institutional practices (e.g., culturing activity) render standardization 
of data collection very difficult [216]. 
Postdischarge surveillance of SSIs has proved to be necessary in many surgical 
operation types: while the length of postoperative hospitalization has decreased, the 
proportion of SSIs appearing after discharge has increased [108, 217-219]. Different 
methods have been used for postdischarge case finding: direct observation of the 
wound by a HCW, patient questionnaires, telephone interviews, review of operating 
logs to examine surgical revisions, examination of hospital readmission data, and 
review of pharmacy data [220]. However, the existing research evidence has not yet 
identified the best method for postdischarge surveillance of SSI. No studies on 
postdischarge SSI surveillance in pediatric patients were available for this review.  
2.3.4 Data analysis 
HAI frequency can be measured with prevalence or incidence rates. To achieve 
meaningful rates, the time period for the numerator (i.e., the number of times an 
event has occurred) and the denominator (i.e., the population from which those 
experiencing the event were derived) must be identical. Prevalence measures the 
active number of HAIs (new or old) present at a specified point in time or during a 
specified period of time. The most common measures of incidence are crude 
cumulative incidence (i.e., the number of new cases of HAI per 100 admissions or 
discharges); crude incidence density, a.k.a. the adjusted infection rate (i.e., the 
number of new cases of HAI per 1,000 patient-days); the specific incidence density, 
which is adjusted for extrinsic risk factors such as exposure to devices (CVC, 
ventilator) or a provider (ICU); and the adjusted incidence density, which is adjusted 
for intrinsic host factors [28, 192, 193, 195]. 
The first surveillance programs collected hospital-wide HAI data and yielded crude 
overall HAI incidence rates using the number of admissions or discharges and 
patient-days as denominators [196]. This approach ignored the fact that the risk 
factors contributing to the development of each HAI type will likely differ [221]. 
The use of site-specific HAI rates controls for this problem, but provides no 
adjustment for variations in patients’ intrinsic and extrinsic infection risks (e.g., a 
high BSI rate in a NICU could be due to a large number of VLBW infants with 
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CVCs, not necessarily to an inadequate BSI prevention program) [196]. To control 
for patients’ extrinsic risk factors, the numerator should represent the number of 
infections that occur in patients exposed to a risk factor (for example CVC-
associated BSIs, i.e., patients with a CVC at the time of the BSI during a defined 
time period), and the denominator should measure the exposure to that particular 
risk factor in the entire population studied (e.g., the number of CVC days during the 
same time period). To control for patients’ intrinsic risk factors, the rates should be 
stratified according to patient subgroups with similar characteristics (e.g., the CVC-
associated BSI rates among neonates with birth weights <1500 g or among those 
born before 32 weeks of gestation). 
2.3.5 Surveillance feedback 
Surveillance results should be reported systematically to ensure information sharing 
with those healthcare providers capable of initiating patient care improvement [193]. 
At least the infection control committee as well as key persons in each clinical 
service, in the nursing administration, and in the hospital administration should be 
informed. Communication should occur on a regular basis, and the reports should be 
simple enough so that the target audience can understand the message in a few 
seconds. Comparing rates with benchmark data is important in terms of helping the 
audience to determine whether their rates are too high. Confidentiality for patients 
and employees must be maintained when reporting results. Intensified reporting, 
such as weekly reporting catheter-related BSIs to the ICU, may also serve as an 
intervention to reduce HAIs [28]. 
The SENIC study showed that 6% of HAIs could be prevented with minimal 
infection control efforts, and stated that a third of HAIs could be prevented with 
well-organized infection control programs [191]. No such large and systematic 
cohort studies have been published after SENIC. However, a systematic review of 
recent multi-modal intervention studies and studies assessing cross-transmission 
concluded that at least 20% of HAIs may be preventable and that, depending on the 
setting, baseline infection rates, and type of infection, the reduction effect ranged 
from 10% to 70% [29].  
The European surveillance networks have been shown to be effective in preventing 
HAIs, reporting reductions of 20%–29% in SSI rates and 24%–57% in ICU-related 
HAI rates [222]. For instance, the German HAI surveillance system (KISS) has 
reported a 29% reduction in relative risk (RR) for VAP, a 20% RR reduction for 
CVC-related BSI, and a 28% RR reduction for SSI in ICUs (NICUs excluded) and 
surgical departments over a three-year period of active surveillance [223]. In the 
NICUs participating in KISS, the BSI rate (both laboratory-confirmed and clinical 
sepsis) decreased 24% overall between the first and third year of surveillance [224]. 
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It is notable that no interventions other than systematic surveillance (with a feedback 
report twice a year and a workshop once a year) were introduced in the KISS 
studies. Thus, the introduction of surveillance likely motivated the HCWs to follow 
infection prevention measures more carefully, which then led to a decrease in 
infection rates [225]. Similar findings have also been reported from single NICUs. 
The introduction of a prevention program in an NICU in Belgium yielded a 71% RR 
reduction for CVC-related BSIs over a four-year period [194]. In an NICU in 
Pittsburgh, USA, improving CVC care practices decreased RR for a CVC-related 
BSI by 37% [226]; similar interventions led to a 55% RR reduction for all HAIs in 
an NICU in Singapore [227]. 
A multidisciplinary collaborative quality improvement project implementing 
“potentially better practices”, conducted in six NICUs participating the Vermont 
Oxford Network [228], also reported a significant decrease in the overall rate of 
BSIs (from 23% to 17%) and in the rate of BSIs caused by CoNS (from 22% to 
12%) in the project NICUs over the four-year study period. Similar decline was not 
seen in the 66 other NICUs that participated in the Vermont Oxford Network and 
served as a comparison group. Unlike the surveillance networks, this study reported 
BSIs as proportions (%, number of infants with infection per total number of 
infants), providing thus no adjustment, and only the first BSI episode for each 
patient was included in the study. However, the BSI definition used was close to the 
CDC definition of a laboratory-confirmed BSI. 
2.3.6 Public reporting of healthcare-associated infection rates 
Demands for improved quality of health care, including a reduction in adverse 
events, have increased during the past two decades [229]; in the US, even a claim 
for zero tolerance to HAIs has been put forth [230]. Mandatory public reporting has 
been argued to promote overall improvement in the quality of health care by 
enabling consumers to make conscious choices about their health care based on this 
information [231]. However, the accuracy of the performance measurement may 
raise concern: variations in hospital structure (e.g., staffing level, infection control 
activity, demographic characteristics), care factors (e.g., CVC care practices), and 
patient factors each directly or indirectly influence HAI outcomes [232]. 
Underreporting infections may also become a cause of concern, particularly if the 
pressure of publicly available data is added to a process that already tends to miss 
cases, as the NNIS evaluation study showed [233]. The process of producing 
comparable rates requires standardization of these factors: using uniform definitions 
and surveillance protocols, performing consistent and accurate case finding, 
controlling patient factors by risk-adjustment methods, and calculating site-specific 
rates [202, 234], which should be kept in mind when implementing public reporting.  
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Several states in the US have implemented a mandatory reporting policy of HAIs 
since 2003 and to date, the majority of states have introduced legislation for 
mandatory public reporting [231]. In the UK, surveillance of some HAIs (namely 
methicillin-resistant S. aureus BSIs, Clostridium difficile-associated diseases, 
glycopeptide-resistant enterococci, and orthopedic SSIs) was made compulsory, 
including public reporting of the rates [235]. The effectiveness of public reporting in 
HAI prevention must still be proven as the evidence available to date is inconclusive 
[231]. However, public and political awareness of HAIs could raise policymakers’ 
interest in infection control, and hopefully also bring more resources into the field. 
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3 AIMS OF THE STUDY 
The purpose of this study was to obtain detailed information on pediatric HAIs at the 
Hospital for Children and Adolescents (HCA), Helsinki University Central Hospital, 
the largest children’s hospital in Finland, in order to support HAI surveillance and 
prevention activities in the future. 
 
The specific objectives were: 
1. To evaluate the clinical and epidemiologic features of nosocomial BSIs as 
well as the distribution and antimicrobial susceptibilities of the causative 
pathogens (I).  
2. To describe clusters of S. marcescens infections in the NICU between 
December 1999 and July 2002, to determine whether a connection existed 
between the clusters, and to identify risk factors for S. marcescens infection 
or colonization (II). 
3. To describe a clonal outbreak caused by C. parapsilosis in the NICU during 
a 12-year period, and to study the development of fluconazole resistance in 
the causative clone during the long-term use of fluconazole prophylaxis 
(III).  
4. To determine the HAI rate among Finnish pediatric patients who underwent 
open-heart cardiac surgery. We aimed to identify the HAIs contracted 
during the postoperative hospital stay. A postdischarge study was conducted 
to determine whether extended surveillance would be needed in this patient 
group in the future (IV). 
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4 MATERIALS AND METHODS 
A short summary of the study methods, the patients studied, and the HAIs identified 
in studies I–IV appears in Table 7. 
4.1 DESCRIPTION OF THE HOSPITAL AND THE 
NEONATAL INTENSIVE CARE UNIT 
All the studies were conducted at the HCA, which is a tertiary care referral pediatric 
center with ca. 15,000 annual admissions. The hospital provides specialty care in the 
following pediatric areas: cardiology, gastroenterology, hematology and oncology (a 
21-bed ward and an outpatient unit), infectious diseases, intensive care (a 10-bed 
PICU), neonatology (a 16-bed and an 8-bed NICU providing level III and level II 
care, and a 16-bed unit providing level II and level I care), nephrology, neurology, 
pulmonology, and surgery. Some functions, namely the care of serious heart 
conditions, open-heart surgery, and organ transplants, are nationally centered in this 
hospital, serving a population of 5.3 million. 
The 16-bed NICU, the setting for the outbreak investigations, has approximately 500 
annual admissions, of which 25% to 30% are VLBW infants. The unit consists of 
five rooms, each with at least one sink, and hand disinfectant dispensers available at 
each bed. An alcohol-based hand rub is used before and after any patient contact, 
and gloves are routinely used during aseptic procedures to avoid contact with 
secretions during procedures such as endotracheal suction. Blood samples for 
culture are drawn from a peripheral vessel by venipuncture whenever an infection is 
suspected. The empirical antimicrobial treatment used for suspected cases of 
septicemia during the investigations was a combination of ampicillin and netilmicin. 
All patients with either suspected or verified candidemia were treated with 
amphotericin B; since June 1999, liposomal amphotericin B was used routinely.
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4.2 SURVEILLANCE METHODOLOGY FOR BLOODSTREAM 
INFECTIONS OF THE FINNISH HOSPITAL INFECTION 
PROGRAM (I, IV) 
4.2.1 In-hospital surveillance of bloodstream infections 
The surveillance module for healthcare-associated BSIs of SIRO began in 1998. In the 
beginning, four hospitals volunteered to participate; in 2007, ten hospitals were 
reporting BSIs to SIRO. Hospital participation is voluntary and confidential. Feedback 
is available for the participating hospitals through the project web site, which can only 
be accessed with a personal user name and password. Each participating hospital has 
access to its own data as well as to aggregated data. 
The CDC definitions of nosocomial BSI were used, and only laboratory-confirmed BSIs 
were included in this study [195] (Table 5). BSIs were classified as ‘primary’ when no 
focal source other than vascular catheter(s) was identified within 48 hours before the 
blood culture. ‘Secondary BSI’ referred to a BSI that developed as a consequence of a 
documented infection focus at another body site (i.e., the same microorganism was 
cultured from blood and another body site within a week). ‘Polymicrobial BSI’ referred 
to infections in which more than one microorganism was recovered from the blood 
within a 48-hour period. Newborn BSIs were further classified as ‘early-onset’ when the 
first positive blood culture was obtained before the age of three days (72 hours), or as 
‘late-onset’ if it was obtained at the age of three days or later. A written protocol was 
provided in Finnish, explaining all the definitions in detail. 
For case finding, local ICNs regularly reviewed the laboratory database for positive 
blood culture results. They were also instructed to visit wards every week and to 
obtain additional information from patient charts and medical and nursing staff. SIRO 
provided training in surveillance methodology before beginning the surveillance. 
Additionally, an opportunity to consult the SIRO team staff by phone when needed 
and meetings at least once a year were provided.  
For each patient with a BSI, clinical information and microbiological data were 
recorded by the local ICNs on a standardized case-record form, which was sent 
monthly to the national center. The following data were included: the patient’s unique 
national identity number (indicating age and sex), dates of admission and discharge, 
date of BSI diagnosis, place (ward code) where the BSI was reported, causative 
microorganisms and their sensitivity to antimicrobial agents, and the underlying 
conditions (newborn status, hematological/solid malignancy, surgery, presence of a 
CVC, ICU stay). Newborn status was defined as an age of 28 days or less at the time 
 45 
of the blood culture; all patients who entered the operating room were recorded as 
having undergone surgery. Only patients hospitalized for at least 24 hours in the ICU 
before the occurrence of BSI were considered to have been exposed to intensive care. 
All BSIs that became evident during the ICU stay or within 48 hours after discharge 
from the ICU were defined as related to intensive care. 
4.2.2 Data management in the national database 
The SIRO staff checked the BSI reports for errors and contacted the local ICNs if 
needed before entering the data into the SIRO database. By using the patients’ unique 
national identity numbers, the data were linked to the National Population Information 
System to obtain a particular patient’s survival at 7 and 28 days from the first positive 
blood culture. 
 
4.3 SURVEILLANCE OF HEALTHCARE-ASSOCIATED 
BLOODSTREAM INFECTIONS (I) 
4.3.1 Data sources 
SIRO data from 1999 through 2006 were available from HCA. A chart review was 
performed to obtain information on antimicrobial treatment and the causes of death for 
patients who died within seven days from the first positive blood culture. 
4.3.2 Analysis and statistics 
Neonatal early-onset infections were excluded from the analysis. Both antibiotic-
resistant and intermediately susceptible organisms were considered resistant when 
resistance percentages were calculated. Univariate analysis of categorical variables 
was conducted using the chi-square test with Yates’ correction or Fisher’s exact test, 
as appropriate. Continuous variables were analyzed with the Student’s t test or the 
Mann-Whitney U test, depending on the sample distribution. The Kruskal-Wallis test 
was used to compare several groups. Data were analyzed with Epi Info software 
(version 6.04, CDC, Atlanta, GA, USA) and SPSS software (version 14.0, Chicago, 
IL, USA). 
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4.4 OUTBREAK STUDIES (II,III) 
4.4.1 Outbreak descriptions and case definitions 
S e r r a t i a  m a r c e s c e n s  o u t b r e a k  ( I I )  
Two blood cultures positive for S. marcescens were identified in the NICU in February 
2000. Thereafter, samples for screening cultures were obtained from the trachea or 
pharynx, rectum, and skin of all neonates in the NICU, and neonates with S. marcescens 
infection or colonization were cohorted. Patients in the cohort were cared for using 
standard precautions, and hand hygiene was emphasized. Nurses were also cohorted 
whenever possible. The outbreak ceased rapidly during the following month. In 
September and October 2000, two new S. marcescens cases were detected, the first of 
which was a BSI. In addition, a third cluster of three S. marcescens BSIs was recorded 
in the summer of 2002 (Figure 2). The two latter clusters ceased spontaneously without 
the introduction of specific control measures after their detection. 
A case-control study was performed to identify risk factors for S. marcescens infection 
or colonization. A review of microbiology laboratory records revealed a positive 
culture for S. marcescens as early as 31 December 1999; therefore, a case-patient was 
defined as a patient in the NICU with at least one culture positive for S. marcescens 
between December 1999 and February 2000. A control-patient was defined as a 
patient admitted to the NICU between 8 December 1999 and 3 February 2000 who 
stayed in the NICU for at least 72 hours (i.e., to ensure sufficient time for exposure) 
and yet had no cultures positive for S. marcescens. The patients included in the case-
control study were identified through a retrospective review of the NICU log and the 
microbiology laboratory reports. For these patients, the length of stay in the NICU, the 
length of stay in the unit prior to detection of S. marcescens, the duration of 
mechanical ventilation prior to the first isolation (case-patients only; for control 
patients, the total duration of mechanical ventilation was considered), and exposure to 
indwelling devices, nutrition, and antibiotics were recorded. Furthermore, information 
regarding maternal infections prior to delivery as well as the delivery room location 
was collected from the hospital database. 
Environmental samples were taken on 3 February 2000 from all sinks and taps of the 
two rooms where all of the infected or colonized patients had been located. 
Additionally, a sample was taken in September 2000 from the breast milk of the 
mother of a neonate with S. marcescens BSI. 
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Figure 2. 
Patients infected or colonized with Serratia marcescens in the neonatal intensive care unit 
between December 1999 and July 2002. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C a n d i d a  p a r a p s i l o s i s  o u t b r e a k  ( I I I )  
The NICU had suffered from nosocomial C. parapsilosis infections since 1989. 
Fluconazole prophylaxis was introduced temporarily, and the outbreak seemed to 
cease [146]. Between May 1992 and July 1994, no positive cultures for C. 
parapsilosis were found in the NICU. After this, new cases of C. parapsilosis 
infections or colonizations emerged constantly in the NICU during the years 1994–
2000, and in September 2000, the number of patients infected or colonized with C. 
parapsilosis in the NICU began to rise again (Figure 3). 
A cohort study was conducted to assess risk factors for C. parapsilosis BSI. All 
patients treated in the NICU between September 2000 and December 2001 who had at 
least one positive culture for C. parapsilosis were identified through a retrospective 
review of the NICU log and the microbiology laboratory reports. Demographic and 
clinical data on the patients were reviewed, recording the length of stay in the NICU, 
the length of stay prior to the first positive culture for C. parapsilosis, the duration of 
mechanical ventilation and nasal continuous positive airway pressure treatment prior 
to detection of C. parapsilosis, exposure to indwelling devices, information on 
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nutrition, and the use of antimicrobial agents. Data were also collected on surgical 
procedures preceding a positive culture for C. parapsilosis, as well as on maternal 
infections and antimicrobial treatments prior to delivery. The patients were 
categorized into three groups: i) patients with BSI, ii) patients with clinical signs of 
superficial infections, and iii) colonized patients. The annual number of admissions 
and patient-days in the NICU was obtained from the hospital administration.  
Environmental samples for culture were taken twice in April 2001 (48 samples from 
48 sites) to identify potential inanimate reservoirs, such as incubator ports and interior 
surfaces, water taps, sinks, ventilatory equipment, and computer keyboards. Air 
sampling was carried out in two rooms with an SAS Super 100 sampler (PBI S.p.A., 
Milan, Italy), in which 1 m3 of air was impacted onto glucose-agar plates. 
 
Figure 3. 
Fluconazole use (grams delivered to the unit) and rates of patients with Candida 
parapsilosis infection or colonization in the neonatal intensive care unit during 1991–2001. 
BSI = bloodstream infection. 
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reintroduced with a higher daily dosage (6 mg/kg) to control the still ongoing outbreak. 
From December 1991 to February 1993, fluconazole was used with a dosage of 6 mg/kg 
twice weekly. After that, infants with birth weights under 1,000 g were given 
fluconazole prophylaxis (6 to 12 mg/kg daily). In late 2000, prophylaxis was extended to 
cover all infants treated in the NICU, but soon afterwards, the first C. parapsilosis 
isolates with reduced susceptibility to fluconazole were found, and the prophylaxis was 
stopped. In November 2002, however, prophylaxis was reintroduced (3 mg/kg daily for 
all infants born before week 28 of gestation) due to the increased number of C. 
parapsilosis infections. Fluconazole use was assessed based on hospital pharmacy 
records and calculated as the number of grams delivered to the NICU annually. 
4.4.3 Microbiological methods 
S e r r a t i a  m a r c e s c e n s  o u t b r e a k  ( I I )  
The genomic relatedness of S. marcescens isolates was analyzed by pulsed-field gel 
electrophoresis (PFGE). Genomic DNA was prepared in agarose blocks as described 
previously [236] and digested with 10 U of restriction endonuclease XbaI (Boehringer, 
Mannheim, Germany) at room temperature for approximately 18 hours. The resulting 
DNA fragments were separated with a CHEF-DR III electrophoresis apparatus (Bio-
Rad, Hercules, CA, USA) on 1% Sea Kem agarose (FMC BioProducts, Rockland, 
ME, USA) using a two-phase program: phase 1 for 10 hours, with initial and final 
switching times of 5 and 15 seconds, and phase 2 for 15 hours, with initial and final 
switching times of 15 and 45 seconds, respectively. PFGE profiles differing by fewer 
than four bands were interpreted as identical or closely related. 
C a n d i d a  p a r a p s i l o s i s  o u t b r e a k  ( I I I )  
Blood samples were incubated in pediatric BacT/Alert blood culture bottles (Organon 
Technica Durham, NC, USA) for six days. Aliquots from positive bottles were Gram-
stained and subcultured on Sabouraud’s glucose agar at 37°C. All other clinical 
samples were inoculated on Sabouraud’s glucose agar (supplemented with penicillin 
and streptomycin) and incubated at 28°C and 37°C for seven days. Yeast isolates were 
subcultured on Sabouraud’s glucose agar and incubated for 24 h at 35°C. All isolates 
were identified by standard methods, including germ tube formation, ID 32C 
identification panels (bioMerieux, Marcy l’Etoile, France), and morphology on 
Czapek-Dox Tween 80 agar and on CHROMagar plates (CHROMagar Co., Paris, 
France). Bloodstream isolates were preserved in 85% milk–15% glycerol tubes at 
−70°C for further characterization. 
Environmental swabs were cultured on glucose-peptone agar plates for 96 h at 30°C. 
Yeasts were identified by a standard methodology [237]. 
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All stored bloodstream isolates of C. parapsilosis obtained from different patients in 
the NICU between November 1990 and June 2002 (n = 26) were sent to the University 
of Iowa, USA, for genotyping and antifungal susceptibility testing. This collection 
contained three BSI isolates from the initial outbreak [146] obtained in 1990 and 
1991, and 23 isolates obtained between 1994 and 2002.  
All 26 BSI isolates were fingerprinted by Southern blot hybridization with the use of a 
complex DNA fingerprinting probe Cp3-13 [238] according to the methods described 
previously [239, 240]. The digested DNA was electrophoresed in a 0.7% agarose gel. 
The C. parapsilosis strain J940043 served as a reference. The gels were transferred to 
a Hybond N+ membrane (Amersham, Piscataway, NJ, USA) by blotting, and 
autoradiographed after hybridization. Autoradiogram images were digitized into the 
DENDRON software database [241]. The processed hybridization patterns were then 
automatically scanned to identify all bands and to link common bands. The patterns of 
all test isolates were compared in a pairwise fashion, and the similarity coefficient 
(SAB) between the patterns of every pair of isolates A and B was computed. An SAB of 
0.0 represents total unrelatedness (no common bands) between isolates A and B, an 
SAB of 1.0 represents an identical match of all bands between isolates A and B, and 
increasing values of SAB from 0.1 to 0.9 represent increasing levels of similarity.  
The antifungal susceptibilities of the C. parapsilosis BSI isolates to fluconazole were 
tested with the Clinical and Standard Laboratory Institute (formerly the National 
Committee for Clinical Laboratory Standards) M27-A2 broth microdilution 
method[242]. 
4.4.4 Analysis and statistics 
The data were analyzed with Epi Info software (version 6.04b; CDC, Atlanta, GA, 
USA) (II, III). For categorical variables, proportions were compared using the chi-
square test with Yates’ correction or Fisher’s exact test, as appropriate. The 
continuous variables were analyzed using the Student’s t test or the Mann-Whitney 
test, depending on the sample distribution. Logistic regression analysis was performed 
using SPSS software (version 11.0; SPSS, Chicago, IL, USA) to model the odds ratios 
(OR) with 95% confidence intervals [56] (II). Pearson correlation coefficients were 
calculated to assess the relationship between the rates of C. parapsilosis BSIs and 
fluconazole consumption in the NICU over time (III). 
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4.5 HEALTHCARE-ASSOCIATED INFECTIONS AFTER OPEN-
HEART SURGERY IN CHILDREN (IV) 
4.5.1 Data sources 
All patients who underwent open-heart cardiac surgery from 1 January 2000 through 
31 December 2002 in the HCA were observed. Procedure-associated data from the 
Finnish Research Registry of Pediatric Cardiac Surgery [243] were utilized. 
Procedures were grouped according to the Risk Adjustment in Congenital Heart 
Surgery (RACHS-1) method, previously used to assess institutional performance by 
comparing observed and expected short-term mortality rates within risk categories 
[244]. Additionally, the following data were obtained from the hospital databases: age, 
gender, length of hospitalization, operation code, type of operation (urgent vs. 
elective), wound class, American Society of Anesthesiologists (ASA) score, and 
duration of operation. The NNIS risk index was calculated from these last three. 
The HAIs were searched from several sources: from the in-hospital HAI register, from 
the microbiology laboratory log, and from SIRO (BSIs). A chart review was 
performed for all identified SSI cases to confirm that the SSI was linked to the surgery 
and that the CDC definitions were met. The viral epidemics during the study period 
were identified by reviewing the microbiology laboratory reports. 
Patients’ families received a standardized postdischarge questionnaire at discharge 
from the cardiology ward. The follow-up period for SSIs was 30 days after the 
procedure. Questions were also asked about gastrointestinal and respiratory symptoms 
with an onset within 72 hours after discharge. 
4.5.2 Analysis and statistics 
For categorical variables, proportions were compared using the chi-square test with 
Yates’ correction or Fisher’s exact test, as appropriate. The continuous variables were 
analyzed with the Mann-Whitney test. Linear-by-linear associations were analyzed 
using the Cochran-Armitage test for trend. Explanatory covariables with a P value of 
less than 0.2 in univariate analysis were included in multivariable logistic regression 
analysis. Akaike and Bayesian Information Criteria for model selection were used. 
The analyses were carried out using SPSS (version 15.0, SPSS, Chicago, IL, USA). 
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4.6 ETHICAL ASPECTS 
The Ministry of Social Affairs and Health, the National Research and Development 
Center for Welfare and Health, and the Finnish Data Protection Authority approved 
the SIRO study plan and authorized the SIRO surveillance (I). The HCA 
administration provided written consent for the review of the charts of the patients 
who died within seven days after the positive blood culture. The outbreak 
investigations (II, III) were conducted as a part of the infection control activities at the 
HCA, thus no ethics committee approval was required for these studies. The ethics 
committee of the HCA did, however, approve the research plan of the study for 
postoperative HAI identification (IV). 
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5 RESULTS 
5.1 SURVEILLANCE OF HEALTHCARE-ASSOCIATED 
BLOODSTREAM INFECTIONS (I) 
5.1.1 Characteristics of patients with bloodstream infections 
A total of 833 nosocomial BSIs in 694 patients were detected during the study period. 
Of the newborn infections, 94 (22%) were early-onset infections, which were 
excluded from the analysis. The remaining 739 BSIs in 600 patients were analyzed. 
The median age of the patients was 48 days; 53% of them were male. The most 
common underlying factors were ICU stay (51%), newborn status (43%), and surgery 
(26%).  
 
Figure 4. 
Annual rates of nosocomial bloodstream infections among patient subpopulations in the 
Hospital for Children and Adolescents during 1999–2006. HEMA = hematology-oncology 
unit, PICU = pediatric intensive care unit, NEONAT = neonatology units, OTHER = all other 
wards providing acute care. 
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The overall annual nosocomial BSI rate in the hospital was 1.6 infections per 1,000 
patient-days (range by year, 1.2–2.1), or 5.7 per 1,000 discharges (range by year, 4.3–
7.1). The rate of BSIs was highest among patients treated in the hematology unit 
(average annual rate, 4.9 BSIs/1,000 patient-days) and in the neonatology unit 
(average annual rate, 3.2 BSIs/1,000 patient-days) (Figure 4). Of the BSIs, 699 (95%) 
were primary and 40 (5%) were secondary. The skin and subcutaneous tissue (29%), 
the gastrointestinal tract (19%), and the urinary tract (17%) were the most common 
sources of secondary BSIs (unpublished data). CVC data was available for 580 (83%) 
primary BSIs and 75% of those were CVC-associated. In total, 27,279 blood samples 
were obtained for culture (median 62; range by year, 48–91 cultures per 1,000 patient-
days), and 27 BSIs were confirmed per 1,000 blood cultures (range by year, 18–36). 
No association was found between the annual rates of cultures performed and BSIs 
detected (Spearman’s correlation coefficient (r) = 0.3, p = 0.65) 
5.1.2 Microbiological features 
A total of 825 isolates were recovered from blood cultures obtained during the 739 
BSI episodes. Of the causative organisms, 627 (76%; range by year, 67%–84%) were 
Gram-positive, 151 (18%; range by year, 15%–27%) Gram-negative, and 47 (6%; 
range by year, 1%–13%) were fungi. The annual proportions of fungal and Gram-
positive infections varied significantly (p <0.01 for each) (unpublished data). Three 
(0.4%) of the bacterial isolates were anaerobes. The most common pathogens were 
CoNS, S. aureus, and Candida species. CoNS were the most common pathogens in all 
patient groups (Figure 5).  
Resistance to methicillin was detected in 86% of CoNS isolates, but in none of the S. 
aureus isolates. No resistance to vancomycin was found among the staphylococci or 
enterococci tested. When resistance to ceftazidime served as a marker for the potential 
presence of extended-spectrum betalactamases, 2% of both E. coli and Klebsiella 
isolates were potential carriers of these enzymes. 
5.1.3 Patient outcome 
Information on survival was available for 725 (98%) patients, 19 (3%) of whom died 
within a week after the onset of the BSI, and 37 (5%) of whom died within a month. 
Of the 19 charts of the patients who died within seven days after the first positive 
blood culture, 18 were available for review. The majority (13/18, 72%) had septicemia 
as a cause of death. Ten (56%) patients were newborns, and six of them were born 
prematurely. Three (12%) patients had a hematological malignancy and six (33%) 
exhibited a congenital condition as an underlying predisposing factor. Fourteen (78%) 
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received appropriate empirical antimicrobial treatment after the clinical BSI diagnosis. 
Of those whose empirical treatment was inappropriate, two patients had candidemia 
and only received antibacterial treatment, one had no symptoms of a septic infection 
and the diagnosis was only apparent post mortem, and one with a BSI caused by 
cefuroxime resistant Enterobacter cloacae was treated with cefuroxime only.  
 
Figure 5. 
Distribution of the 825 nosocomial bloodstream infection isolates by patient subpopulations.  
PICU = pediatric intensive care unit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The case-fatality proportions were highest for BSIs caused by Streptococcus 
agalactiae, Enterobacter species, Pseudomonas, and Candida species (Table 8). The 
patients who died were more likely to have been admitted to an ICU (4% vs. 1%, p = 
0.02) or to have undergone surgery (5% vs. 2%, p = 0.03). 
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Table 8. 
The most common pathogens among 825 isolates from patients with a nosocomial 
bloodstream infection (BSI) at the Hospital for Children and Adolescents during 1999–2006, 
and case-fatality ratios at 7 and 28 days from the date of the first positive blood culture 
result for a particular patient. 
 
 
No. (%) of isolates 
associated with 
 case-fatality 
Microorganism No. (%) of isolates At day 7 At day 28* 
Coagulase-negative staphylococcia) 430 (52.1) 4 (1) 13 (3) 
Staphylococcus aureus 55 (6.7) 1 (2) 1 (2) 
Candida speciesb) 47 (5.7) 4 (9) 6 (13) 
Enterococcus speciesc) 45 (5.5) 1 (2) 3 (7) 
Escherichia coli 41 (5.0) – – 3 (7) 
Viridans group streptococci 31 (3.8) 1 (3) 1 (3) 
Klebsiella species 25 (3.0) 1 (4) 1 (4) 
Pseudomonas species 21 (2.5) 2 (10) 3 (14) 
Enterobacter species 19 (2.3) 3 (16) 3 (16) 
Streptococcus agalactiae 6 (0.7) 1 (17) 1 (17) 
* Unpublished data 
a) 328/430 (76%) Staphylococcus epidermidis 
b) 20/47 (43%) Candida albicans, 19/47 (40%) Candida parapsilosis, 2/47 (4%) non-specified  
   non-albicans, and 6/47 (13%) non-specified Candida isolates 
c) 35/45 (78%) Enterococcus faecalis, 9/45 (20%) Enterococcus. faecium, and  
   1/45 (2%) Enterococcus gallinarum  
5.2 INVESTIGATION OF THE S. MARCESCENS OUTBREAK (II) 
5.2.1 Description of the clusters and patient volume in the NICU  
During the first cluster, 11 patients with positive cultures for S. marcescens were 
identified during a period of five weeks: one infant with BSI, three with conjunctivitis, 
and seven who were colonized (Figure 2). The second cluster included one infant with 
both BSI and conjunctivitis, and one colonized infant four weeks later. The third 
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cluster lasted for eight weeks, and included two infants with BSI, two with 
conjunctivitis and two with S. marcescens colonization. The infants had been born in 
several different hospitals, and no epidemiologic link associated to the place of birth 
could be found. 
The NICU was overcrowded during all of the clusters; the number of patients in the 
NICU exceeded the official number of beds more than every second day (mean 
occupation rates 108%, 105% and 118% for the respective months), and the mean 
occupation rate of the level III beds was 150% during the two first clusters. The mean 
occupation rate in the NICU during the six-month period before the first cluster was 
95%, and during a three-year period covering all the clusters (from June 1999 till May 
2002) 97%; the mean occupation rate of the level III beds was 116% and 110%, 
respectively (unpublished data). The overcrowding led to a higher patient-to-nurse 
ratio, because no additional nurses were available. 
5.2.2 Case-control study 
The case-control study included 11 case-patients and 27 control-patients from the first 
cluster. There were no differences between the two groups in gender, place of birth, 
and type of delivery. The results of the univariate analysis appear in Table 9. The 
significant factors found in the analysis were entered into a logistic regression model 
where only maternal infection (OR, 18.7; CI95, 1.49 to 236.7) remained an 
independent risk factor associated with S. marcescens infection or colonization. 
 
Table 9.  
Univariate analysis of factors associated with Serratia marcescens infection or colonization. 
* Data presented in medians (range) 
† As measured prior to the first positive culture for S. marcescens or discharge from the NICU 
‡ Data presented in numbers (%); OR 9.3, CI95% (1.5–68) 
Factor Cases  (n = 11)    
Controls  
(n = 27)  P 
Birth weight (g)* 835 (405-2120) 1547 (395-4120) 0.01 
Gestational age (weeks)* 26 (25-33) 31 (25-41) < 0.01 
Duration of mechanical ventilation 
(d)*† 8 (1-46) 2 (0-39) 0.02 
Duration of antimicrobial therapy (d)* 19 (0-42) 0 (0-33) 0.02 
Maternal infections prior to delivery‡ 8 (73%) 6 (22%) < 0.01 
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5.2.3 Genotyping  
There were 24 isolates from 15 patients available for PFGE typing: 12 isolates from 7 
patients of the first cluster, 6 isolates from 2 patients of the second cluster, and 6 
isolates from 6 patients of the third cluster. All but one (11 of 12) of the isolates of the 
first cluster were identical. Six isolates obtained in the fall of 2000 were identical, but 
differed from those of the first cluster. The six isolates of the third cluster were 
indistinguishable from each other, but differed from the isolates of both the first and 
the second clusters. 
One of the four environmental samples taken from a sink during the first cluster tested 
positive for S. marcescens. PFGE proved that this environmental sample contained the 
epidemic strain of the first cluster. The breast milk sample obtained during the second 
cluster also tested positive for S. marcescens, but was unavailable for genotyping. 
 
5.3 INVESTIGATION OF THE C. PARAPSILOSIS OUTBREAK (III) 
5.3.1 Cohort study 
There were 624 admissions, including 155 VLBW infants, in the NICU during the 16-
month study period. A total of 56 patients were infected or colonized with C. 
parapsilosis, representing 9% of all infants treated in the NICU. The study included 
10 patients with BSIs, 15 patients with superficial infections (6 with conjunctivitis, 6 
with wound infections, 1 with a skin infection, and 2 with urinary tract infections), and 
24 patients who were colonized. Six (60%) of the 10 patients with BSIs, and four 
(27%) of the 15 patients with superficial infections were colonized with C. 
parapsilosis before the infection. The characteristics of the patients with positive 
cultures for C. parapsilosis appear in Table 10. 
The analysis showed no differences between the groups by gender, type of delivery, or 
mortality. Prematurity, low birth weight, and umbilical catheterization were identified 
as risk factors for C. parapsilosis BSIs. Half (5/10) of the patients with BSIs received 
fluconazole at the time of the first positive blood culture, as did 27% (4/15) of the 
patients with other infections at the time of the positive culture. Of the colonized 
patients, 33% (8/24) received fluconazole at the time of the first positive culture. 
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5.3.2 Fluconazole use and positive Candida cultures 
Fluconazole use in the NICU increased after the initial outbreak in 1989–1991, and 
remained high from 1994 until 2000, when the first C. parapsilosis strains with 
reduced susceptibility were detected. When fluconazole use was reduced, the rate of 
C. parapsilosis infections increased over time (Figure 3). From 1994 to 2001, a 
negative correlation between fluconazole consumption and the rate of C. 
parapsilosis BSIs emerged (r = −0.79; p = 0.009).  
During the 12-year period (1991–2002), few sporadic findings of fungi other than C. 
parapsilosis or C. albicans were detected. C. parapsilosis was the most prevalent 
Candida species in the NICU to cause BSIs. Only sporadic cases of C. albicans 
BSIs (zero to one per year from 1990 to 2000 and two in 2001) occurred prior to 
2002, when six C. albicans BSIs were detected. No infections caused by Candida 
krusei or Candida glabrata occurred. 
5.3.3 Genotyping and susceptibility testing 
All 26 BSI isolates were identical in the DNA fingerprinting analysis, and thus 
represented a single strain of C. parapsilosis. When a dendrogram based on the SAB 
values that included the 26 isolates from the NICU of the HCA and 16 randomly 
selected C. parapsilosis isolates from a worldwide collection at the University of 
Iowa was generated, the 26 HCA isolates clustered at an SAB of 1.00. 
Overall, 19 of the 26 BSI isolates were susceptible (minimal inhibitory 
concentration, MIC ≤8 mg/liter), 5 of 26 were susceptible dose dependent (MIC = 
16 to 32 mg/liter), and 2 of 26 were resistant (MIC ≥64 mg/liter) to fluconazole. 
Over time, the initially susceptible isolates derived from a single strain became 
progressively less susceptible to fluconazole until resistant isolates emerged in the 
last two years. The proportion of isolates with the less susceptible phenotype was 
significantly higher among the isolates collected in 2001 and 2002 than among those 
collected between the years 1990 and 2000 (p = 0.02). 
Of the 48 environmental samples cultured, only one tested positive for C. 
parapsilosis; this sample was obtained from the base of a tap in a room where an 
infant with a C. parapsilosis BSI had been cared.
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5.4 HEALTHCARE-ASSOCIATED INFECTIONS AFTER 
PEDIATRIC OPEN-HEART SURGERY (IV) 
5.4.1 Characteristics of study patients and procedures 
The study included 614 procedures performed in 511 patients, excluding those who 
died within 24 hours after surgery. The median age at surgery was six months. The 
distribution of the procedures by the RACHS-1 score appears in Table 11 
(unpublished data). The postdischarge study population consisted of 467 procedures 
performed in 432 patients, 324 (75%) of whom received the questionnaire. 
5.4.2 Postoperative infections 
A total of 80 HAIs were detected in 66 patients (in-hospital HAI rate, 6.3 per 1,000 
patient-days): 27 SSIs, 20 BSIs, 4 pneumonias, 17 gastrointestinal infections, 3 eye 
infections, 3 urinary tract infections, and 6 skin or subcutaneous tissue infections. 
The majority (78%) of the SSIs were superficial; four (15%) were deep incisional 
infections and two (7%) mediastinitis (mediastinitis rate, 0.3 per 100 procedures). 
The in-hospital SSI rate was 4.4 per 100 procedures. The 20 BSIs, 19 of which were 
primary (primary BSI rate, 1.5 per 1,000 patient-days), were identified in 19 (4%) 
patients. 
A total of 291 postdischarge questionnaires (90%) were returned. Seven superficial 
SSIs confirmed by a physician or a nurse were identified. Respiratory symptoms 
within 72 hours after discharge were reported in 29 (10%) of 291 patients, 7 of 
whom had been readmitted to the hospital. Gastrointestinal symptoms were also 
reported in 29 patients, 5 of whom had been rehospitalized. The median length of 
rehospitalization was three days (range, 1 to 8 days). A total of 9 of the patients with 
respiratory symptoms and 18 of the patients with gastrointestinal symptoms were 
postoperatively hospitalized during a viral outbreak (caused by respiratory syncytial 
virus, norovirus or rotavirus) at the ward. 
5.4.3 Risk factors for surgical site infections 
In the univariate analysis, patients with an SSI were younger and smaller and had a 
longer preoperative stay than that of patients with no SSI. The NNIS risk index 
score did not stratify the patients, but the SSI rate increased significantly in terms of 
both ASA and RACHS-1 scores (p <0.01 for both). 
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Prolonged preoperative stay, the ASA score, and the RACHS-1 score served as 
explanatory covariables in the multivariable logistic regression analysis. The two 
models with the best information criteria were used. Preoperative stay (OR = 2.7; 
CI95%, 1.1–6.6) and ASA (OR = 2.4; CI95%, 1.1–5.3) were significant risk factors in 
one model, but in the other model, none of the covariables was significant by itself. 
 
Table 11.  
Surgical procedures by Risk Adjustment in Congenital Heart Surgery (RACHS-1) score 
[244]. 
 
RACHS-1 score Type of surgery No. of procedures 
1 Atrial septal defect (ASD) 44  
 Others 8  
    
2 Ventricular septal defect (VSD) repair 87  
 Glenn shunt 52  
 Total repair of tetralogy of Fallot 36  
 ASD and VSD repair 11  
 Others 35  
    
3 Repair of transitional or complete atrioventricular canal 40  
 Right/left ventricular-to-pulmonary artery conduit 31  
 Total cavo-pulmonary connection (TCPC) operation 31  
 Arterial switch operation 27  
 Valve replacement 17  
 Repair of coarctation and VSD closure 15  
 Others 60  
    
4 Arterial switch operation with VSD closure or repair of subpulmonary stenosis 10  
 Repair of total anomalous pulmonary veins ≤30 days of age 9  
 Atrial septectomy 7  
 Others 22  
    
5 Miscellaneous 3  
    
6 Norwood operation 40  
 Others 7  
No classification  22  
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6 DISCUSSION 
6.1 SURVEILLANCE OF HEALTHCARE-ASSOCIATED 
BLOODSTREAM INFECTIONS 
6.1.1 Bloodstream infection rate 
Hospital-wide studies on pediatric nosocomial BSIs are scarce; only three such reports 
were available, a multi-center report from the US [54], one from an Israeli tertiary care 
center [53], and one from a Mexican general hospital [245]. We found a BSI rate of 
5.7 infections per 1,000 discharges, whereas the overall rates of other studies ranged 
from 5.3 to 29.4 infections per 1,000 discharges. However, direct comparisons of 
infection rates are difficult due to significant differences in patient populations, in the 
hospital infrastructures as well as in medical supplies and practices. 
Consistent with the previous studies, we found that BSI rates varied widely 
depending on the patient subpopulations viewed. Despite the overall stability in 
annual rates, hematology and neonatology units had heavily fluctuating rates which 
were considerably higher than those of other units (Figure 4). As NICUs generally 
differ from other units in a children’s hospital, and since special attention should be 
paid to this particular patient group, the national surveillance systems (e.g., 
NNIS/NHSH and KISS) have developed separate standardized protocols for these 
high-risk units and provide specific reference data for NICUs to enable comparisons 
[200]. The patient populations of individual NICUs may differ significantly, and 
stratification of the infection rates in proportion to gestational age (or birth weight) 
groups or device days aids in avoiding misinterpretation of the rates. 
6.1.2 Microbiological aspects 
Gram-positive bacteria, especially CoNS, predominated in our study. This finding 
was in line with the report from the US [54], while Gram-negative pathogens 
predominated in the other two studies [53, 245]. Neither methicillin resistance in S. 
aureus isolates nor vancomycin resistance in E. faecium isolates was detected during 
the study. The finding differed from the corresponding rates of the US study (16% 
and 11%, respectively) [54], but concurred with the national resistance rates: the 
proportion of methicillin-resistant S. aureus isolates among all S. aureus BSI 
isolates was <1% during 1999–2003, and 3% during 2004–2006, and until the end of 
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2006, only six vancomycin-resistant enterococci isolates had been identified in 
Finland [246, 247]. 
6.1.3 Patient outcomes 
The overall mortality rate in our study was 5%, substantially lower than the rates of 
9% to 38% reported earlier. The case-fatality proportion for most pathogens did not 
increase after the first week after the BSI onset. However, for Candida infections, 
the proportion increased from 9% on day 7 to 13% on day 28. All patients in our 
study who had candidemia and died (n = 6) exhibited severe underlying conditions 
(3 premature newborns, 2 patients with recent open-heart surgery, and 1 with a 
hematological malignancy). The chart review showed that two of the four patients 
who died within seven days after the positive blood culture received empirical 
antimicrobial therapy, which included no antifungal agents. This may have affected 
the unfavorable outcome, and suggests that the possibility of a fungal infection 
should be kept in mind when an empirical BSI treatment is introduced in patients 
with complicated medical conditions. Clinical predictive models have been 
developed to help the decision making; for example a retrospective multicenter 
cohort study (including 100 NICUs) concluded that empirical antifungal therapy 
should be considered for all premature neonates born before week 25 of gestation, 
for all thrombocytopenic neonates, and for those neonates born between weeks 25 
and 27 of gestation who have been exposed to third-generation cephalosporins or 
carbapenems in the seven days before the blood culture [248].  
6.2 OUTBREAK INVESTIGATIONS (II, III) 
6.2.1 Source and spread of the pathogens 
No common source or reservoir for the outbreaks was identified other than the 
infected and colonized infants themselves. The genotyping results confirmed three 
independent clusters of S. marcescens, and that the same strain of C. parapsilosis 
persisted for over a decade in the NICU. Both findings suggest that infected and 
colonized patients served as reservoirs, and that the pathogens were most likely 
transmitted horizontally via the hands of the HCWs in the NICU. 
The positive environmental cultures (one for S. marcescens, obtained from a sink, 
and one for C. parapsilosis, obtained from the base of a tap) were probably found as 
a consequence of washing contaminated hands or utensils prior to taking the sample, 
which further supports the assumption that the pathogen colonized the hands of the 
 65 
HCWs. The positive breast milk sample in the second S. marcescens cluster could 
suggest that the milk was a common source for this cluster, but since the strain was 
unavailable for genotyping, exploring this hypothesis was impossible. 
6.2.2 Risk factors 
Both investigations identified the risk factors commonly associated with HAIs: low 
birth weight or gestational age, or prolonged need for mechanical ventilation 
(Tables 9 and 10). The patients with S. marcescens infection or colonization had 
also received antimicrobial agents for a longer time than those without S. 
marcescens, but since the information on antibiotic use for each patient was 
collected for the entire hospital stay, this was more likely a consequence of the 
infection rather than a cause. Maternal infection and subsequent treatment with 
antibiotics prior to delivery was an independent risk factor for S. marcescens, as 
previous studies have also reported [123, 125]. The selection pressure following 
maternal antimicrobial treatment may have led to the overgrowth of S. marcescens, 
and thus contributed to the colonization of some of the infants. However, genotyping 
confirmed that the outbreak occurred mostly due to cross-transmission, which 
cannot be explained by maternal characteristics or risk factors. 
6.2.3 Role of hand hygiene, overcrowding and understaffing 
Horizontal transmission most likely occurs via the hands of HCWs and thus 
emphasizes the role of hand hygiene. Improved hand hygiene compliance has been 
reported to be crucial in controlling, for example, a large outbreak of C. parapsilosis 
BSIs in adults [249]. Studies have shown adherence to hand hygiene guidelines to be 
below 50% usually [162], and the carriage of different types of pathogens on the 
hands of the HCWs has also proved to be common in NICUs [172, 174] (Table 3).  
Overcrowding and subsequent understaffing likely contributed to the spreading of S. 
marcescens (II). Previous studies have also described outbreaks or site-specific 
infections associated with increased patient-to-nurse ratios in pediatric settings [143, 
146, 147, 149, 153]. The causality between understaffing and HAIs is complex, and 
defining the optimal patient-to-nurse ratio is difficult; not only the patient case mix 
and the number of HCWs, but also the HCWs’ level of training and their working 
conditions, including the possible job-related dissatisfaction, affect the outcomes 
[147, 250, 251]. 
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6.2.4 Emergence of fluconazole resistance in C. parapsilosis (III) 
Horizontal transmission seems to be especially important for C. parapsilosis, in 
contrast to C. albicans, which is usually acquired vertically from the mother [252]. 
This could be important when considering the implementation of fluconazole 
prophylaxis. Our data support the findings reported by Kaufman et al. [91] that 
prophylaxis could be more effective against C. albicans than against C. parapsilosis. 
The nosocomial acquisition of the latter may more often involve strains endemic to 
the NICU and less susceptible to the prophylactic drug used. 
The emergence of fluconazole resistance and the increase in the proportions of 
intrinsically fluconazole-resistant Candida isolates are a matter of concern when 
prophylaxis is used. Prophylaxis studies conducted in NICUs [91, 94, 101-103] have 
shown no signs of fluconazole resistance or reduced susceptibility regarding C. 
parapsilosis isolates. Some have hypothesized that this phenomenon is due to the 
low total fluconazole doses received [91]. However, all of these studies had a 
considerably shorter study period than ours (up to 6 years vs. 12 years), and resistant 
isolates were observed in our study only in the last two years, after ten years of 
continuous fluconazole prophylaxis use. Given that the 26 BSI isolates represented a 
single genotype, secondary resistance to fluconazole apparently developed after 
continued exposure to fluconazole. 
Large surveillance studies have found no evidence of an overall increase in the rates 
of fluconazole resistance in populations of C. parapsilosis either [253-255]; only 
one study showed a slight decrease in the percentage of fluconazole-susceptible C. 
parapsilosis isolates [256]. A systematic review of randomized controlled 
fluconazole prophylaxis trials suggested that the use of fluconazole prophylaxis 
significantly increased the risk of colonization by strains with reduced susceptibility 
to fluconazole, but the risk for invasive disease caused by such strains did not 
increase [104]. 
Among the ten patients with C. parapsilosis BSIs included in the cohort study, five 
were receiving fluconazole at the time of the first positive blood culture, and two of 
these had isolates with reduced susceptibility to fluconazole. Earlier studies have 
also reported C. parapsilosis to cause candidemia during fluconazole prophylaxis, 
and some of those C. parapsilosis strains were reported to be less susceptible to 
fluconazole [257, 258].  
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6.2.5 Patient outcomes 
Few patients with invasive S. marcescens or C. parapsilosis infections died and 
none of the deaths were attributable to the infections (II, III). Previous studies have 
reported a high case-fatality rate in similar patient populations [90, 126, 129, 135-
137, 151, 152, 154, 159]. One explanation for the low mortality rate for S. 
marcescens may be the early use of empiric therapy for neonates showing symptoms 
of septic infections; most of the S. marcescens isolates were susceptible to 
netilmicin, which was used as part of the first-line therapy. Studies have often 
reported the case-fatality of C. albicans infections to be significantly higher than 
that of C. parapsilosis infections (26%–36% versus 4%–7%) [10, 86], and the 
observed low case-fatality for C. parapsilosis is in line with these reports. 
6.3 HEALTHCARE-ASSOCIATED INFECTIONS AFTER 
OPEN-HEART SURGERY (IV) 
6.3.1 Impact of postdischarge surveillance 
Only slightly more than half of the HAIs were detected during the hospital stay 
(overall HAI rate, 23 per 100 procedures; in-hospital HAI rate, 12 infections per 100 
procedures). The SSI rate was 5.5 per 100 procedures; 20% of the SSIs were 
detected after discharge. As many as 25% of the patients who reported symptoms of 
respiratory or gastrointestinal infections were rehospitalized. 
Symptoms of gastrointestinal and respiratory tract infections arising immediately 
after hospitalization were reported in 22% of the questionnaires and these infections 
accounted for more than a third of all HAIs detected. This suggests that the impact 
of postdischarge surveillance on HAI rates was significant. However, postdischarge 
surveillance is unlikely to help in reducing the nosocomial transmission of viral 
infections. In-hospital surveillance and early outbreak detection to promote the 
implementation of appropriate control measures, for example during seasonal viral 
epidemics, are more likely to be effective tools in controlling these common 
pediatric HAIs. 
6.3.2 Postoperative infection rates 
The in-hospital patient infection rate of 16% in our study was relatively low: the 
overall [in-hospital] rates reported in previous studies were between 16% and 31% 
[22-24]. The SSI rate of 5.5% (in-hospital SSI rate, 4.4%) in this study was in line 
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with the previous findings (Table 1). The BSI rate detected was relatively low 
compared to the rates reported earlier [22-24, 259]. The HAI rates, however, were 
reported differently from study to study, and only the crude patient infection 
proportion was available for comparison, which is likely to be distorted. 
6.3.3 Risk factors for surgical site infections 
Most earlier studies have reported the finding that preoperative hospitalization for 
more than two days increased the risk for SSI [20, 22, 23]; only one of them 
reported no association [21]. The duration of surgery or perfusion time [20-22] and 
having an open chest after the operation [23, 24] were identified as risk factors for 
infection in earlier studies, but we found no such association. The NNIS risk index 
did not stratify our patients according to their risk for SSI, as also described earlier 
[112, 113]. A high procedure complexity score and ASA score seemed to be risk 
factors, but in the multivariable risk factor analysis, the interpretation of the results 
was equivocal due to the small number of SSIs and correlations between the 
variables. Thus, the RACHS-1 score may have provided no advantages in SSI risk 
assessment over the ASA score, and using the RACHS-1 score could simply create 
extra work. 
6.4 UNRESOLVED ISSUES AND FUTURE CONSIDERATIONS 
6.4.1 Surveillance of bloodstream infections (I) 
Unlike many other national surveillance networks nowadays, the BSI surveillance 
data in SIRO is hospital-wide, and no separate surveillance components have been 
established for NICUs or other ICUs. Thus, systematically collected device-
associated data (CVC, urinary catheter, or ventilator usage) or birth weight data for 
NICU patients were unavailable for this study. As many as 75% of the study patients 
with primary BSIs had a CVC at the time of the BSI and the CVC usage rates in 
different HCA units would have been essential for determining the adjusted rates for 
CVC-associated BSIs. The hospital databases turned out to be incomplete regarding 
CVC usage data and also our attempts to obtain the existing data failed due to 
technical problems. Therefore, to adjust the BSI data appropriately for patients’ 
extrinsic and intrinsic risk factors proved impossible, which rendered the assessment 
of variation in the patient population over time impossible and the annual BSI rates 
incomparable. Moreover, our NICU data permitted no international comparisons 
with, for example, the NNIS or the KISS. 
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We detected no reduction in the BSI rates during the eight years of surveillance; the 
overall rate remained fairly stable, but in some units, especially in the NICU, the 
annual rates fluctuated heavily with an alarmingly increasing trend in the most 
recent years (Figure 4). This illustrates the limited capability of overall hospital-
wide rates to reveal true changes in special patient subpopulations. The baseline 
rates for the subpopulations could be even more accurate if adjusted data were 
available. Additionally, adjusting the definitions for special patient groups (e.g., 
neonates) according to clinicians’ expectations could create an atmosphere of 
confidence, and thus facilitate the process of surveillance data acceptance and usage 
among clinicians [206]. To improve the quality of the SIRO data regarding NICUs, 
these issues need to be addressed in the future. 
Surveillance success stories have highlighted the importance of regular feedback 
[223, 229]. Such stories have also been reported from NICUs [194, 224]. Within 
SIRO, continuously updated surveillance data are available through the project web 
site; each hospital has access to its own data (both hospital-wide and on the ward 
level) as well as the aggregated data, which are also presented at annual SIRO 
meetings. SIRO has no resources for the routine analysis of unit-based data, and 
therefore can provide no intensified or targeted feedback. Assistance for the local 
infection control teams is, however, available. This approach seems too weak, but 
the key question – how to convince the local infection control teams and clinicians 
to make full use of the SIRO data – remains to be answered. This could be achieved 
through more specific projects; for example, the validation study for orthopedic SSIs 
within SIRO [260] seemed to generate interest among the local teams, and SSI rates 
have decreased over the following years [261]. Similar interventions could prove 
useful for BSI surveillance as well, especially for special units such as NICUs. For 
instance, a NICU prevalence study could help to clarify the purpose and means of 
surveillance for the staff in patient-care, and thereby also help to improve the quality 
and degree of utilization of the data. 
6.4.2 Limitations regarding data collection (II–IV) 
The outbreak investigations (II, III) were limited due to retrospective data collection: 
some data were incomplete or missing, depending on what had been recorded in the 
patient files. Our study design did not allow assessment of the role of the empiric 
antibiotic policy in the emergence of the outbreaks, because the use of antimicrobial 
agents in the NICU was not studied comprehensively.  
The data of the patients who underwent open-heart surgery (IV) were also 
retrospectively completed, and thus culture-negative HAIs could not be identified. 
The coverage of the postdischarge survey was low, only 52% of the patients with 
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open-heart procedures during the study period were recruited, which could suggest 
that many HAIs with a postdischarge onset were overlooked. Most severe HAIs 
were likely caught, because those patients would probably have been rehospitalized. 
The burden of illness caused by viral infections acquired during hospitalization may, 
however, be even heavier, and the overall HAI rate higher than reported. 
The attempt to measure the workload of HCWs (II) was crude, and thus unlikely to 
be fully descriptive. Proper measurements would, however, require a prospective, 
well-designed study focused on this complex issue; measures of outcomes more 
sophisticated than a HAI may also be needed in the future to determine the optimal 
staff level and mix of skills [150]. 
6.4.3 Compliance with infection control guidelines (I–IV) 
CDC guidelines for the prevention of intravascular catheter-related infections [262], 
first released in 1996 and updated in 2002, provide basic information and evidence-
based recommendations on the use of intravascular devices for HCWs who insert 
catheters and for staff responsible for the surveillance and control of HAIs. Since 
catheters, especially CVCs, are an important risk factor for BSIs, guidelines for 
catheter insertion, care, and maintenance should be developed and implemented in 
all units using CVCs [263]. In addition, enteral feeding should be favored whenever 
possible to minimize parenteral nutrition and catheter use [264]. The approach to 
CVC care in practice, however, seems to vary considerably between the units [265, 
266]. The Finnish Society for Infection Control has contributed to the publication of 
a book containing unofficial national guidelines [267] (adapted from the CDC 
guidelines) on which the local guidelines in Finnish hospitals can be based. A recent 
survey of 29 Finnish adult ICUs showed that 25% of the nurses did not know 
whether such guidelines existed in the ICU, and that only 52% of them performed 
CVC care practices according to the guidelines [268]. 
We performed no monitoring of HCW compliance with hand hygiene or of CVC 
care in our studies. Therefore, identifying or rectifying possible problems in these 
multifactorial areas is beyond the scope of this study. Studying the prevailing 
practices through observation in the NICU during the outbreaks, for example, could 
have helped to reduce cross-transmission. An observational study of CVC care 
practices could also be well-grounded in high-risk units in the future, and should be 
considered especially, if BSI rates appear to increase. Training material, such as 
videos, on CVC care could also encourage stricter adherence to the guidelines. 
Conducting surveillance or other infection control activities makes no sense if no 
corrective actions are taken; in short, “we have met the enemy and he is us” [269]. 
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7 CONCLUSIONS 
1. Hospital-wide BSI rates remained stable over time, but the overall stability 
masked the significant variation among patient subpopulations. CVCs were 
commonly present in primary BSIs. Further studies with adequate data 
adjustments for patient risk factors are needed to examine in greater detail 
the subpopulations with the highest BSI rates (neonatology and hematology 
patients). A systematical evaluation of the prevailing practices, aiming at 
reduced use of parenteral nutrition and CVCs as well as improved CVC 
care, might help to reduce catheter-related BSIs. 
2. Outbreak investigations showed that horizontal transmission was common 
in the NICU. Overcrowding and lapses in hand hygiene likely contributed 
to the spreading of the pathogens. No common source for the outbreaks, 
other than infected and colonized patients, was identified. 
3. The initially susceptible isolates of C. parapsilosis derived from a single 
strain became less susceptible to fluconazole following long-term exposure 
to the drug. Eventually, resistant subclones were found in the NICU after a 
decade of continuous fluconazole use. 
4. Almost one-fourth of the children who underwent open-heart surgery 
acquired at least one HAI. All severe HAIs were detected during 
hospitalization. Viral infections were common and often caused 
rehospitalization. The postdischarge study identified only superficial SSIs 
that did not affect the patient outcome. Thus, routine postdischarge 
surveillance may be unnecessary in this patient group. 
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